

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
20 November 2003 (20.11.2003)

PCT

(10) International Publication Number  
**WO 03/095667 A2**

(51) International Patent Classification<sup>7</sup>: **C12Q 1/00**

(21) International Application Number: PCT/TB03/02419

(22) International Filing Date: 13 May 2003 (13.05.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/380,904 13 May 2002 (13.05.2002) US  
60/429,609 27 November 2002 (27.11.2002) US

(71) Applicant (*for all designated States except US*): **AREXIS AB** [SE/SE]; Arvid Wallgrens Backe, S-413 46 Göteborg (SE).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **HOLMDAHL, Rikard** [SE/SE]; Siriusgatan 2, S-224 57 Lund (SE). **OLOFSSON, Peter** [SE/SE]; Kulgränden 11D, S-226 49 Lund (SE).

(74) Agent: **PLOUGMANN & VINGTOFT A/S**; Sundkrogs-  
gade 9, P.O. Box 831, DK-2100 Copenhagen Ø (DK).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: AUTOIMMUNE CONDITIONS AND NADPH OXIDASE DEFECTS

(57) Abstract: The invention relates to methods and materials involved in diagnosing and treating autoimmune conditions. In particular, the invention relates to methods and materials involved in diagnosing arthritis conditions that are accompanied by an NADPH oxidase deficiency, methods and materials involved in treating, preventing, or delaying the onset of arthritis conditions that are accompanied by an NADPH oxidase deficiency, and methods and materials involved in identifying agonists and antagonists of NADPH oxidase activity.



**WO 03/095667 A2**

## **AUTOIMMUNE CONDITIONS AND NADPH OXIDASE DEFECTS**

### **RELATED APPLICATIONS**

5           This application claims the benefit of U.S. Provisional Application Serial No. 60/380,904, filed May 13, 2002 and U.S. Provisional Application Serial No. 60/429,609, filed November 27, 2002.

### **BACKGROUND**

#### 10    1. *Technical Field*

          The invention relates to methods and materials involved in diagnosing and treating autoimmune conditions. In particular, the invention relates to methods and materials involved in diagnosing arthritis conditions that are accompanied by an NADPH oxidase deficiency, methods and materials involved in treating, preventing, or delaying  
15   the onset of arthritis conditions that are accompanied by an NADPH oxidase deficiency, and methods and materials involved in identifying agonists and antagonists of NADPH oxidase activity.

#### 2. *Background Information*

20           Autoimmune conditions are conditions where a mammal's immune system starts reacting against its own tissues. Such conditions include, without limitation, arthritis (e.g., rheumatoid arthritis (RA)), multiple sclerosis, lupus, autoimmune uveitis, type I diabetes, bronchial asthma, septic arthritis induced with staphylococci or streptococci, and cardiovascular disease involving vasculitis.

25           RA is a chronic inflammatory disease that can be found in about 1-2 % of the population. RA primarily affects peripheral joints where inflammatory synovitis leads to cartilage destruction, bone erosion, and ultimately to joint deformity and loss of joint function. RA is a complex disease in that both environmental factors as well as multiple chromosomal regions are involved in susceptibility to RA. Inducers of arthritis in animal  
30   models include adjuvants, collagen (e.g., collagen type II) (collagen induced arthritis (CIA)), hexadecane (hexadecane induced arthritis (HIA)), oil (e.g., Freund's incomplete

adjuvant), squalene (squalene induced arthritis (SIA), and pristane (pristane induced arthritis (PIA)). Chromosomal regions known to be associated with development of RA include the major histocompatibility complex region. In addition, different genomic regions are known to control different phases of the disease such as onset, severity during the acute onset phase, and the severity of the destruction in the chronic relapsing phase.

### SUMMARY

The invention provides methods and materials related to diagnosing and treating autoimmune conditions such as arthritis (e.g., RA), multiple sclerosis, lupus, autoimmune uveitis, type I diabetes, bronchial asthma, septic arthritis induced with staphylococci or streptococci, and cardiovascular disease involving vasculitis. For example, the invention provides methods and materials involved in diagnosing autoimmune conditions that are accompanied by an NADPH oxidase deficiency, methods and materials involved in treating, preventing, and/or delaying the onset of autoimmune conditions that are accompanied by an NADPH oxidase deficiency, and methods and materials involved in identifying agonists and antagonists of NADPH oxidase activity. Autoimmune conditions that are accompanied by an NADPH oxidase deficiency include, without limitation, arthritis (e.g., RA), multiple sclerosis, lupus, autoimmune uveitis, type I diabetes, bronchial asthma, septic arthritis induced with staphylococci or streptococci, and cardiovascular disease involving vasculitis conditions that coexist with or are caused by a deficiency in NADPH oxidase activity. For the purpose of this invention, the term “arthritis accompanied by NADPH oxidase deficiency” (abbreviated “AANOD”) refers to any arthritis condition that coexists with or is caused by a deficiency in NADPH oxidase activity. Such a deficiency can be the complete lack of NADPH oxidase activity or a partial reduction in NADPH oxidase activity. For example, a mammal can have AANOD when that mammal has arthritis as well as cells that exhibit NADPH oxidase activity to an extent less than that normally exhibited by healthy mammals of the same species. Likewise, a mammal can have multiple sclerosis accompanied by an NADPH oxidase deficiency when that mammal has multiple sclerosis as well as cells that exhibit NADPH oxidase activity to an extent less than that normally exhibited by healthy mammals of the same species.

It is noted that the methods and materials for diagnosing and treating AANOD described herein can be used to diagnose and treat other autoimmune conditions that are accompanied by NADPH oxidase deficiency. For example, the methods and materials described herein can be used to diagnose and treat multiple sclerosis conditions that are accompanied by NADPH oxidase deficiency. In this regard, experimental allergic (autoimmune) encephalomyelitis (EAE) is a useful model for multiple sclerosis.

Diagnosing patients having an autoimmune condition accompanied by an NADPH oxidase deficiency (e.g., AANOD) can help clinicians determine appropriate treatments for those patients. For example, a clinician who diagnoses a patient as having AANOD can treat that patient with medication that improves both the patient's arthritis and NADPH oxidase deficiency. In some cases, a single medication can be used to improve a patient's level of NADPH oxidase activity such that the patient's arthritis symptoms are reduced or relieved. Thus, treating a patient having AANOD by modulating NADPH oxidase activities can improve that patient's health and quality of life by, for example, reducing the symptoms or severity of symptoms associated with arthritis, or delaying the onset of arthritis.

In addition, identifying agonists and antagonists of NADPH oxidase activity can help both clinicians and patients. For example, the methods and materials described herein can be used to identify agents that increase NADPH oxidase activity such that patients with an autoimmune condition accompanied by an NADPH oxidase deficiency (e.g., AANOD) can be treated successfully.

The invention is based on the discovery that arthritis can be associated with or caused by a reduced level of NADPH oxidase activity. For example, development of severe arthritis symptoms in an arthritis animal model can be, at least partially, dependent upon the presence of low NADPH oxidase activity. The invention also is based on the discovery that the reduced level of NADPH oxidase activity responsible for arthritis susceptibility can be caused by sequence variations (e.g., mutated phosphorylation sites) in a polypeptide component (e.g., P47PHOX polypeptide) of a mammal's NADPH oxidase enzyme. In addition, the invention is based on the discovery that mammals prone to develop arthritis can be protected by providing those mammals with normal levels of NADPH oxidase activity. For example, an animal model prone to develop severe arthritis



symptoms can be rescued by providing that animal with a fully functional NADPH oxidase pathway.

In general, the invention features a method for assessing a mammal's susceptibility to develop an autoimmune condition (e.g., arthritis or multiple sclerosis), the method includes: (a) providing, from a mammal, a blood or synovial fluid sample containing a cell; (b) determining the level of NADPH oxidase activity of the cell after contacting the cell with an NADPH oxidase activator; (c) determining whether or not the level is less than a control level of NADPH oxidase activity, wherein the control level is the average amount of NADPH oxidase activity of control cells from a population of mammals without the autoimmune condition (e.g., non-arthritic mammals), and wherein the mammals without the autoimmune condition are from the same species as the mammal; and (d) identifying the mammal as being susceptible to develop the autoimmune condition when the level is less than the control level. The NADPH oxidase activator can be norfloxacin, phosphatidic acid, diacylglycerol, arachidonic acid, phorbol myristate acetate, lysophosphatidylcholine, fMLP, pristane, phytol, octane, decane, undecane, dodecane, tridecane, tetradecane, hexadecane, hexadecene, heptadecane, octadecane, galectin 1, or galectin 3. The level of NADPH oxidase activity can be determined by measuring superoxide or reactive oxygen species. The population can contain at least 10 mammals. Step (c) can include determining whether or not the level is between 5 and 75 percent less than the control level, wherein step (d) includes identifying the mammal as being susceptible to develop the autoimmune condition when the level is between 5 and 75 percent less than the control level. Step (c) can include determining whether or not the level is between 25 and 55 percent less than the control level, wherein step (d) includes identifying the mammal as being susceptible to develop the autoimmune condition when the level is between 25 and 55 percent less than the control level.

In another embodiment, the invention features a method for assessing a mammal's susceptibility to develop an autoimmune condition (e.g., arthritis or multiple sclerosis), the method containing: (a) providing, from a mammal, a blood or synovial fluid sample; (b) determining the level of a blood or synovial fluid component that reflects NADPH oxidase activity; (c) determining whether or not the level is less than a control level, wherein the control level is the average amount of the component in control samples from

a population of mammals without the autoimmune condition (e.g., non-arthritis mammals), and wherein the mammals without the autoimmune condition are from the same species as the mammal; and (d) identifying the mammal as being susceptible to develop the autoimmune condition when the level is less than the control level. The component that reflects NADPH oxidase activity can be malonic dialdehyde.

Another embodiment of the invention features a method for assessing a mammal's susceptibility to develop an autoimmune condition (e.g., arthritis or multiple sclerosis), the method containing determining whether or not a mammal contains a genetic variant of the gene encoding a polypeptide that functions in the NADPH oxidase pathway, where the presence of the genetic variant indicates that the mammal is susceptible to develop the autoimmune condition. The genetic variant can encode a mutant polypeptide. The mutant polypeptide can be a GP91PHOX polypeptide, P22PHOX polypeptide, P40PHOX polypeptide, P47PHOX polypeptide, or P67PHOX polypeptide. For example, the mutant polypeptide can be a P47PHOX polypeptide. The mammal can be a human, and the mutant P47PHOX polypeptide can contain the sequence set forth in SEQ ID NO:6 with at least two amino acid substitutions. The mutant P47PHOX polypeptide can contain an amino acid sequence having an amino acid residue other than valine at the position that aligns with position 106 of SEQ ID NO:4 or an amino acid residue other than threonine at the position that aligns with position 153 of SEQ ID NO:4. The genetic variant can contain a mutation in a regulatory sequence of the gene.

Another embodiment of the invention features a method for diagnosing an autoimmune condition accompanied by NADPH oxidase deficiency (e.g., AANOD or multiple sclerosis accompanied by NADPH oxidase deficiency) in a mammal having an autoimmune condition, the method containing: (a) providing, from the mammal, a sample containing a cell; (b) determining the level of NADPH oxidase activity of the cell after contacting the cell with an NADPH oxidase activator; (c) determining whether or not the level is less than a control level of NADPH oxidase activity, wherein the control level is the average amount of NADPH oxidase activity of control cells from a population of mammals without the autoimmune condition (e.g., non-arthritis mammals), and wherein the mammals without the autoimmune condition are from the same species as the mammal; and (d) identifying the mammal as having the autoimmune condition associated

by NADPH oxidase deficiency when the level is less than the control level. The NADPH oxidase activator can be norfloxacin, phosphatidic acid, diacylglycerol, arachidonic acid, phorbol myristate acetate, lysophosphatidylcholine, fMLP, pristane, phytol, octane, decane, undecane, dodecane, tridecane, tetradecane, hexadecane, hexadecene, heptadecane, octadecane, galectin 1, or galectin 3. The level of NADPH oxidase activity can be determined by measuring superoxide or reactive oxygen species. The population can contain at least ten mammals without the autoimmune condition. Step (c) can include determining whether or not the level is between 5 and 75 percent less than the control level, wherein step (d) includes identifying the mammal as being susceptible to develop the autoimmune condition associated by NADPH oxidase deficiency when the level is between 5 and 75 percent less than the control level. Step (c) can include determining whether or not the level is between 25 and 55 percent less than the control level, wherein step (d) includes identifying the mammal as being susceptible to develop the autoimmune condition associated by NADPH oxidase deficiency when the level is between 25 and 55 percent less than the control level.

Another embodiment of the invention features a method for diagnosing an autoimmune condition associated by NADPH oxidase deficiency (e.g., AANOD or multiple sclerosis accompanied by NADPH oxidase deficiency) in a mammal having an autoimmune condition, the method containing: (a) providing, from the mammal, a blood or synovial fluid sample; (b) determining the level of a blood or synovial fluid component that reflects NADPH oxidase activity; (c) determining whether or not the level is less than a control level, wherein the control level is the average amount of the component in control samples from a population of mammals without the autoimmune condition (e.g., non-arthritis mammals), and wherein the mammals without the autoimmune condition are from the same species as the mammal; and (d) identifying the mammal as having the autoimmune condition associated by NADPH oxidase deficiency when the level is less than the control level.

Another embodiment of the invention features a method for diagnosing an autoimmune condition accompanied by NADPH oxidase deficiency (e.g., AANOD or multiple sclerosis accompanied by NADPH oxidase deficiency) in a mammal having an autoimmune condition, the method includes: (a) providing a blood or synovial fluid

sample from the mammal; (b) determining the level of a blood or synovial fluid component that reflects NADPH oxidase activity; (c) determining whether or not the level is less than a control level of NADPH oxidase activity, wherein the control level is the average amount of NADPH oxidase activity of control cells from a population of mammals without the autoimmune condition, and wherein the mammals without the autoimmune condition are from the same species as the mammal; and (d) identifying the mammal as having the autoimmune condition accompanied by NADPH oxidase deficiency when the level is less than the control level. The component that reflects NADPH oxidase activity can be malonic dialdehyde.

Another embodiment of the invention features a method for diagnosing an autoimmune condition accompanied by NADPH oxidase deficiency (e.g., AANOD or multiple sclerosis accompanied by NADPH oxidase deficiency) in a mammal having an autoimmune condition, the method including determining whether or not the mammal contains a genetic variant of the gene encoding a polypeptide that functions in the NADPH oxidase pathway, wherein the presence of the genetic variant indicates that the mammal has the autoimmune condition accompanied by NADPH oxidase deficiency. The genetic variant can encode a mutant polypeptide. The mutant polypeptide can be a GP91PHOX polypeptide, P22PHOX polypeptide, P40PHOX polypeptide, P47PHOX polypeptide, or P67PHOX polypeptide. For example, the mutant polypeptide can be a P47PHOX polypeptide. The mammal can be a human, and the mutant P47PHOX polypeptide can contain the sequence set forth in SEQ ID NO:6 with at least two amino acid substitutions. The mutant P47PHOX polypeptide can contain an amino acid sequence having an amino acid residue other than valine at the position that aligns with position 106 of SEQ ID NO:4 or an amino acid residue other than threonine at the position that aligns with position 153 of SEQ ID NO:4. The genetic variant can contain a mutation in a regulatory sequence of the gene.

In another aspect, the invention features a method for treating a mammal having an autoimmune condition accompanied by NADPH oxidase deficiency (e.g., AANOD or multiple sclerosis accompanied by NADPH oxidase deficiency), the method including administering, to the animal, an agent that enhances NADPH oxidase activity. The agent can be norfloxacin, phosphatidic acid, diacylglycerol, arachidonic acid, phorbol myristate

acetate, lysophosphatidylcholine, fMLP, pristane, phytol, octane, decane, undecane, dodecane, tridecane, tetradecane, hexadecane, heptadecane, octadecane, galectin 1, or galectin 3. Alternatively, the agent can be a more polar derivative of the afore-mentioned compounds. For example, the agent can be an alkene derivative of the afore-mentioned compounds (e.g., undecene, hexadecene), or an acid derivative of the afore-mentioned compounds. In one embodiment, hexadecene is used. In another embodiment, undecane is used. The agent may be administered intra-dermally, intra-peritoneally, or intra-nasally.

In another embodiment, the invention features the use of an agent in the manufacture of a medicament to treat an autoimmune condition accompanied by NADPH oxidase deficiency (e.g., AANOD or multiple sclerosis accompanied by NADPH oxidase deficiency), wherein the agent enhances NADPH oxidase activity in a mammal. The agent can be norfloxacin, phosphatidic acid, diacylglycerol, arachidonic acid, phorbol myristate acetate, lysophosphatidylcholine, fMLP, pristane, phytol, octane, decane, undecane, dodecane, tridecane, tetradecane, hexadecane, heptadecane, octadecane, galectin 1, or galectin 3. Alternatively, the agent can be a more polar derivative of the afore-mentioned compounds. For example, the agent can be an alkene derivative of the afore-mentioned compounds (e.g., undecene, hexadecene), or an acid derivative of the afore-mentioned compounds. In one embodiment, hexadecene is used. In another embodiment, undecane is used.

Another embodiment of the invention features a method of formulating a medicament for the treatment of an autoimmune condition, the method including: (a) contacting a sample comprising cells or a cellular fraction having NADPH activity with a test agent, (b) determining the level of NADPH oxidase activity in the sample, (c) determining whether or not the level is greater than a control level of NADPH oxidase activity, wherein the control level is the amount of NADPH oxidase activity in a control sample lacking the test agent, (d) identifying the test agent as an agent useful for treatment of the autoimmune condition when the level of NADPH oxidase activity is greater than the control level, and (e) formulating a medicament from the agent for the treatment of the autoimmune condition. The autoimmune condition can be arthritis or multiple sclerosis.

Another aspect of the invention features a method for identifying an agent that activates NADPH oxidase activity in a cell, wherein the cell is from a non-human animal susceptible to arthritis induction, the method containing determining whether or not the level of NADPH oxidase activity increases in the cell after the cell is treated with a test agent, wherein an increase in the level indicates that the test agent activates NADPH oxidase activity. The cell can be a cell from a DA rat. The cell can be a lymphocyte. The non-human animal can be susceptible to pristane induced arthritis, or collagen induced arthritis, or adjuvant induced arthritis, or oil induced arthritis, or hexadecane induced arthritis, or squalene induced arthritis, or avidine induced arthritis. The level of NADPH oxidase activity can be determined by measuring superoxide or reactive oxygen species, e.g., as with a cytochrome C assay or WST-1 assay or a flow cytometer (e.g., FASC) based assay using, e.g., dihydrorodamine 123 (DHR-123).

In another embodiment, the invention features a method for identifying an agent useful in the treatment of an autoimmune condition, the method including: (a) contacting a sample comprising cells or a cellular fraction having NADPH activity with a test agent, (b) determining the level of NADPH oxidase activity in the sample, (c) determining whether or not the level is greater than a control level of NADPH oxidase activity, wherein the control level is the amount of NADPH oxidase activity in a control sample lacking the test agent, and (d) identifying the test agent as an agent useful for treatment of the autoimmune condition when the level of NADPH oxidase activity is greater than the control level. The autoimmune condition can be arthritis or multiple sclerosis.

In another embodiment, the invention features a method for identifying an agent useful in the treatment of an autoimmune condition, the method including: (a) contacting a sample comprising cells or a cellular fraction having NADPH activity with a test agent, (b) contacting the sample with an NADPH oxidase activator, (c) determining the level of NADPH oxidase activity in the sample, (d) determining whether or not said level is greater than a control level of NADPH oxidase activity, wherein the control level is the amount of NADPH oxidase activity in a control sample treated with the activator in the absence of the test agent, and (e) identifying the test agent as an agent useful for treatment of the autoimmune condition when the level of NADPH oxidase activity is greater than the control level. The autoimmune condition can be arthritis or multiple sclerosis.

In another embodiment, the invention features a method for identifying an agent that enhances NADPH oxidase activity in a cell, wherein the cell is from a non-human animal susceptible to arthritis induction, the method including: (a) contacting the cell with an NADPH oxidase activator and a test agent to form a test cell; (b) determining the level of NADPH oxidase activity in the test cell; (c) determining whether or not the level is greater than a control level of NADPH oxidase activity, wherein the control level is the amount of NADPH oxidase activity in a control cell treated with the activator in the absence of the test agent; and (d) identifying the agent as enhancing NADPH oxidase activity when the level is greater than the control level. The cell can be a cell from a DA rat. The cell can be a lymphocyte. The non-human animal can be susceptible to pristane induced arthritis or collagen induced arthritis, or adjuvant induced arthritis, or oil induced arthritis, or hexadecane induced arthritis, or squalene induced arthritis, or avridine induced arthritis. The NADPH oxidase activator can be norfloxacin, phosphatidic acid, diacylglycerol, arachidonic acid, phorbol myristate acetate, lysophosphatidylcholine, fMLP, pristane, phytol, octane, decane, undecane, dodecane, tridecane, tetradecane, hexadecane, hexadecene, heptadecane, octadecane, galectin 1, or galectin 3. The level of NADPH oxidase activity can be determined by measuring superoxide or reactive oxygen species, e.g., by a cytochrome C or WST-1 assay or a flow cytometer (e.g., FASC) based assay using, e.g., dihydrorodamine 123 (DHR-123).

In another embodiment, the invention features a method for identifying an agent that inhibits NADPH oxidase activity in a cell, wherein the cell is from a non-human animal susceptible to arthritis induction, the method containing: (a) contacting the cell with an NADPH oxidase activator and a test agent to form a test cell; (b) determining the level of NADPH oxidase activity in the test cell; (c) determining whether or not the level is less than a control level of NADPH oxidase activity, wherein the control level is the amount of NADPH oxidase activity in a control cell treated with the activator in the absence of the test agent; and (d) identifying the agent as inhibiting NADPH oxidase activity when the level is less than the control level. The cell can be a cell from a DA rat. The cell can be a lymphocyte. The non-human animal can be susceptible to pristane induced arthritis, or collagen induced arthritis, or oil induced arthritis, or hexadecane induced arthritis, squalene induced arthritis, or avridine induced arthritis. The NADPH

oxidase activator can be norfloxacin, phosphatidic acid, diacylglycerol, arachidonic acid, phorbol myristate acetate, lysophosphatidylcholine, fMLP, pristane, phytol, octane, decane, undecane, dodecane, tridecane, tetradecane, hexadecane, hexadecene, heptadecane, octadecane, galectin 1, or galectin 3. The level of NADPH oxidase activity  
5 can be determined by measuring superoxide or reactive oxygen species.

In another embodiment, the invention features a method for identifying an agent that modulates T-cell activation (e.g., reduces or enhances T-cell activation), the method including: (a) determining whether or not a test agent increases NADPH oxidase activity; and (b) classifying the test agent as an agent that reduces T-cell activation when the test  
10 agent increases NADPH oxidase activity.

Another aspect of the invention features a rat congenic to a second rat, wherein at least one locus differs genetically between the rat and the second rat, wherein the second rat is susceptible to arthritis induction, wherein the rat contains T-cells from the second rat, and wherein the rat has arthritis. The rat can be a DA.E3c12-/- rat. The second rat  
15 can be a DA rat. The at least one locus can contain nucleic acid that encodes a P47PHOX polypeptide. In some embodiments, no more than one locus can differ genetically between the rat and the second rat. In those cases, the locus can contain nucleic acid that encodes a P47PHOX polypeptide.

Another aspect of the invention features a nonhuman mammal having a deficient  
20 NADPH oxidase pathway, where the nonhuman mammal exhibits symptoms of an autoimmune disease. The autoimmune disease may be arthritis, multiple sclerosis, lupus, autoimmune uveitis, type I diabetes, bronchial asthma, septic arthritis induced with staphylococci or streptococci, or cardiovascular disease involving vasculitis. For example, the nonhuman animal may exhibit symptoms of arthritis. The arthritis may be  
25 adjuvant induced arthritis, collagen induced arthritis, pristane induced arthritis, hexadecane induced arthritis, avridine induced arthritis, or squalene induced arthritis, or oil induced arthritis. The deficient NADPH oxidase pathway may be indicated by a reduced NADPH oxidase activity. The reduced NADPH oxidase activity may be a result of a mutant polypeptide where the mutant polypeptide functions in the NADPH oxidase  
30 pathway. For example, the mutant polypeptide may be a GP91PHOX polypeptide, P22PHOX polypeptide, P40PHOX polypeptide, P47PHOX polypeptide, or P67PHOX



polypeptide. For example, the mutant polypeptide can be a P47PHOX polypeptide. The mutant P47PHOX polypeptide can contain the sequence set forth in SEQ ID NO:6 with at least two amino acid substitutions. The mutant P47PHOX polypeptide can contain an amino acid sequence having an amino acid residue other than valine at the position that aligns with position 106 of SEQ ID NO:4 or an amino acid residue other than threonine at the position that aligns with position 153 of SEQ ID NO:4. In other embodiments, the reduced NADPH oxidase activity may be a result of a deletion of the gene or locus encoding Ncf1 (*p47phox*). The deletion may be heterozygous or homozygous in the nonhuman mammal. The nonhuman mammal may be a mouse.

In another embodiment, the invention features a method of screening an agent to determine if the agent delays the onset of arthritis. The method includes: (a) providing a nonhuman mammal having a deficient NADPH oxidase pathway; (b) administering to the nonhuman mammal the agent; (c) inducing arthritis in the nonhuman mammal; and (d) determining if the agent delays the onset of arthritis in the nonhuman mammal. The deficient NADPH oxidase pathway may be as described previously. Determining if the agent delays the onset of arthritis may include steps such as: (a) determining a day of onset of arthritis value for the nonhuman mammal; and (b) comparing the day of onset of arthritis value for the nonhuman mammal with a control day of onset of arthritis value. The control day of onset of arthritis value may be determined by determining a day of onset of arthritis value for a control nonhuman mammal to which the agent has not been administered. The day of onset of arthritis in the nonhuman mammal may be considered delayed if it is later than the control day of onset value. The induced arthritis may be adjuvant induced arthritis, collagen induced arthritis, pristane induced arthritis, hexadecane induced arthritis, avridine induced arthritis, squalene induced arthritis, and/or oil induced arthritis.

Another method of the invention includes screening an agent to determine if the agent treats arthritis. The method includes (a) providing a nonhuman mammal having a deficient NADPH oxidase pathway, where the nonhuman mammal exhibits symptoms of an arthritis (e.g., adjuvant induced arthritis, collagen induced arthritis, pristane induced arthritis, hexadecane induced arthritis, avridine induced arthritis, squalene induced arthritis, or oil induced arthritis); (b) administering to the nonhuman mammal the agent;

and (c) determining if the agent treats arthritis in the nonhuman mammal. Such a determining step may involve (a) calculating an arthritis score in the nonhuman mammal; and (b) comparing the arthritis score with a control arthritis score. The control arthritis score may be determined by calculating an arthritis score for a control nonhuman mammal to which the agent has not been administered. The agent may be determined to treat arthritis if the arthritis score in the nonhuman animal is less than the control arthritis score.

In another embodiment, a method of screening an agent to determine if the agent prevents arthritis is provided. The method includes: (a) providing a nonhuman mammal having a deficient NADPH oxidase pathway; (b) administering to the nonhuman mammal the agent; (c) administering a compound known to induce arthritis to the nonhuman mammal; and (d) determining if the agent prevents arthritis induced by the compound in the nonhuman mammal. Determining if the agent prevents arthritis may include evaluating said nonhuman mammal for symptoms of arthritis. Such an evaluation may occur for a period of time, e.g., for up to 20 days, up to 30 days, up to 50 days, or up to 70 days. Determining if the agent prevents arthritis may include comparing any symptoms of arthritis and their day of onset with the symptoms and day of onset of a control nonhuman mammal to which said agent has not been administered. The compound known to induce arthritis may be an adjuvant, collagen, pristane, hexadecane, avridine, squalene, and/or oil. Collagen may be type II collagen; the oil may be incomplete Freund's adjuvant; and the adjuvant may be mycobacterial-derived.

In another embodiment, a method for identifying an agent that inhibits NADPH oxidase activity in a lymphocyte, wherein the lymphocyte is from a DA rat. The method includes: (a) contacting the lymphocyte with PMA and a test agent to form a test cell; (b) determining the level of NADPH oxidase activity in the test cell by measuring superoxide; (c) determining whether or not the level is less than a control level of NADPH oxidase activity, wherein the control level is the amount of NADPH oxidase activity in a control cell treated with the PMA in the absence of the test agent; and (d) identifying the agent as inhibiting NADPH oxidase activity when the level is less than the control level.

In another embodiment, a non-DA rat comprising heterologous T-cells from a non-human animal susceptible to arthritis induction, wherein the non-DA rat has arthritis. The rat can be an E3 rat. The non-human animal can be a DA rat.

Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the present specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.

Other features and advantages of the invention will be apparent from the following detailed description, and from the claims.

15

## DESCRIPTION OF DRAWINGS

Figure 1 is a graph comparing the mean clinical arthritis scores determined at day 10, 14, 19, 24, and 28 after pristane injection of DA rats, DA.E3chr12+/- rats, and DA.E3chr12-/- rats.

Figure 2 is a physical map of the *Pia4* region constructed using PAC clones and EST clones.

Figure 3 is an alignment of the E3 and DA *p47phox* cDNA sequences amplified from the RNA of E3 and DA rats.

Figure 4 is a set of bar graphs demonstrating that plasma levels of cartilage oligomeric matrix protein (COMP; Figure 4A) and  $\alpha$ 1-acid glycoprotein (AGP; Figure 4B) were significantly lower in DA.E3chr12 congenic rats than in DA littermate control rats ( $p < 0.005$ ).

Figure 5 is a set of absorbance curves illustrating production of reactive oxygen species in a DA rat (Figure 5A), an E3 rat (Figure 5B), a DA.E3c12+/- rat (Figure 5C), and a DA.E3c12-/- rat (Figure 5D).

Figure 6 is a graph illustrating increased severity of arthritis in rats treated with an NADPH inhibitor, diphenyleneiodonium chloride (DPI).

Figure 7 is a bar graph illustrating that rats treated with DPI had greater accumulated arthritis scores than control rats.

Figure 8 is a bar graph illustrating that transfer of Concanavalin A (ConA) activated T-cells from a DA rat gave rise to severe arthritis in DA littermate control rats (DA), in DA.E3chr12 +/- rats (HET), and in DA.E3chr12 -/- rats (E3).

Figure 9 is a set of graphs showing the activation of the oxidative burst from rat E3 peritoneal cells (Figure 9A) and HL60 cells (Figure 9B) after treatment with alkanes *in vitro*. The oxidative burst is measured with the WST-1 assay.

Figure 10 is a set of graphs demonstrating the arthritis inducing effects of alkanes 12-31 days after administration. Figure 10A demonstrates the Mean score; Figure 10B demonstrates the Additive score; and Figure 10C demonstrates the Maximum score according to the extended scoring system described herein after injection of the alkanes intradermally at the base of the tail.

Figure 11 is a set of graphs demonstrating the severity of PIA in DA rats treated with undecane or undecanol at varying time points. Figure 11A demonstrates the Mean score; Figure 11B demonstrates the Additive score; and Figure 11C demonstrates the Maximum score.

Figure 12 is a set of graphs demonstrating the severity of hexadecane induced arthritis after treatment with hexadecene on day -5 or day +5. Figure 12A demonstrates the Mean score; Figure 12B demonstrates the Additive score; and Figure 12C demonstrates the Maximum score.

Figure 13 is a bar graph demonstrating the severity of arthritis in rats treated with radioactively- labeled oils.

Figure 14 is a bar graph illustrating the tissue distribution of <sup>14</sup>C-labeled oils at 10, 20, and 30 days post-injection. The activity was measured in a  $\beta$ -counter for one minute. Note that LN = lymph nodes.

Figure 15 is a bar graph illustrating the distribution of [1-<sup>14</sup>C]-hexadecane to the lymph nodes as measured in a  $\beta$ -counter (Beckman) for one minute.

Figure 16 is a set of bar graphs demonstrating the effect of phytol on the development of EAE in DA rats treated with phytol on day -10, -5 or day +5. Figure 16A

demonstrates the Additive score; Figure 16B demonstrates the Maximum score. Olive oil was used as a control.

Figure 17 is a set of graphs demonstrating the effect of phytol treatment on development of PIA with different routes of phytol administration. Figure 17A

5 demonstrates the Mean score; Figure 17B demonstrates the additive score; and Figure 17C demonstrates the Maximum score.

Figure 18 is a set of graphs illustrating the onset of CIA in *Ncf1* (*p47phox*) deficient mice, both homozygous and heterozygous, as compared to B10.Q mice. Figure 18A demonstrates the Mean score; Figure 18B demonstrates the Maximum score; and

10 Figure 18C demonstrates the Additive score.

Figure 19 is a bar graph showing the mean day of onset of CIA in *Ncf1* deficient mice, both homozygous and heterozygous, as compared to B10.Q mice.

Figure 20 is a bar graph showing the serum COMP levels in *Ncf1* deficient mice, both homozygous and heterozygous, as compared to B10.Q mice following induction of CIA by injection of rat CII.

15

Figure 21 is a bar graph showing the levels of anti collagen antibodies in *Ncf1* deficient mice, both homozygous and heterozygous, as compared to B10.Q mice following induction of CIA by injection of rat CII.

Figure 22 is a graph demonstrating the effect of phytol treatment of CIA using different routes of administration.

20

Figure 23 is a set of graphs demonstrating the effect of treatment of active PIA using different active agents and routes of administration. 200  $\mu$ L of either phytol (Figure 23A) or undecane (Figure 23B) were administered at day 21 and day 26.

25

## DETAILED DESCRIPTION

The invention provides methods and materials related to diagnosing and treating autoimmune conditions (e.g., arthritis). Specifically, the invention provides methods and materials involved in diagnosing mammals susceptible to arthritis and mammals having AANOD. In addition, the invention provides methods and materials involved in treating mammals susceptible to arthritis and mammals having AANOD. Further, the invention

30

provides methods and materials involved in identifying agonists and antagonists of NADPH oxidase activity.

*1. Diagnosing Mammals Susceptible to Arthritis*

5           The invention provides methods for assessing a mammal's susceptibility to developing arthritis. The mammal can be a human, monkey, goat, horse, cow, pig, dog, cat, mouse, or rat. Briefly, a mammal's susceptibility to developing arthritis can be determined by examining the level of NADPH oxidase activity present within the mammal's cells. This level of NADPH oxidase activity then can be compared with a  
10       control level, and the mammal can be classified as being susceptible to developing arthritis if the level of NADPH oxidase in the mammal's cells is lower than the control level as further described below.

          The level of NADPH oxidase activity in a mammal's cells can be determined using any known method. For example, NADPH oxidase activity can be assessed by  
15       measuring the amount of reactive oxygen species generated. As used herein, the term "reactive oxygen species" includes, without limitation, partially reduced species of oxygen such as superoxide ion ( $O_2^{\cdot -}$ ), hydrogen peroxide ( $H_2O_2$ ), hydroxyl radical ( $OH^{\cdot}$ ) and hydroxide ion. The amount of reactive oxygen species generated can be measured using standard methods such as those that involve measuring cytochrome C reduction,  
20       lucigenin luminescence, luminol-luminescence, and DCFDA fluorescence. Alternatively, the level of NADPH oxidase activity in a mammal's cells can be determined by measuring the level of components known to reflect NADPH oxidase activity. Such components include, without limitation, circulating malonic dialdehyde.

          After determining the level of NADPH oxidase activity present within the  
25       mammal's cells, this level of NADPH oxidase activity can be compared with a control level of NADPH oxidase activity for that particular species. The control level of NADPH oxidase activity for a particular species is the average level of NADPH oxidase activity measured in cells from a population of healthy members from that particular species. In the case of humans, the control level of NADPH oxidase activity can be the average level  
30       of NADPH oxidase activity in cells from 5, 10, 20, 30, 40, 50, or more healthy humans. If the level of NADPH oxidase activity in a mammal's cells is lower than the control

level, then the mammal can be classified as being susceptible to arthritis. For example, a mammal having an NADPH oxidase activity that is no more than about 85 (e.g., no more than 75, 65, 55, 45, 35, 25, 15, 5, or less) percent of the control level can be classified as being susceptible to arthritis.

- 5           Alternatively, a mammal (e.g., human) having impaired NADPH oxidase activity can be classified as being susceptible to arthritis. For example, a human having impaired NADPH oxidase activity such that a sample of about  $1 \times 10^6$  granulocytes from that human exhibits less than 0.3 to 0.4 absorbance units (550 nm) of cytochrome C reduction after about 7 minutes of treatment with 0.01  $\mu\text{M}$  fMLP can be classified as being
- 10           susceptible to arthritis. In one embodiment, a human having cells with no more than about 85 (e.g., no more than 75, 65, 55, 45, 35, 25, 15, 5, or less) percent of this level of activity is classified as being susceptible to arthritis. The cells can be treated with activators other than fMLP such as agents that affect cellular signaling by modulating phosphorylation (e.g., PMA), agents that destabilize cell membranes (e.g., pristane,
- 15           squalene, phytol, and hexadecane), and agents that bind cell surface receptors (e.g., galectin1 and galectin 3).

- Any type of sample can be used to determine the level of NADPH oxidase activity in a mammal's cells. For example, the sample can be blood, synovial fluid, or lymph fluid containing cells (e.g., PBMCs) having NADPH oxidase activity. Cells having
- 20           NADPH oxidase activity include, without limitation, macrophages, neutrophils, granulocytes, polymorphonuclear leukocytes, and mononuclear cells. Standard methods can be used to obtain such samples from the mammal. For example, a blood sample can be obtained by venous puncture. The sample can be subjected to any necessary standard preparatory procedures before assessing NADPH oxidase activity. For example, a blood
- 25           sample containing cells can be subjected to centrifugation and/or washing steps to isolate cells from which the level of NADPH oxidase activity can be measured.

- In another embodiment, a mammal's susceptibility to developing arthritis can be determined by examining at least a portion of the amino acid sequence of a polypeptide within the mammal's NADPH oxidase pathway. Such polypeptides include, without
- 30           limitation, GP91PHOX polypeptides, P22PHOX polypeptides, P40PHOX polypeptides, P47PHOX polypeptides, and P67PHOX polypeptides. For example, the amino acid

sequence of the mammal's P47PHOX polypeptide can be determined. Any method can be used to determine the amino acid sequence of a polypeptide. For example, standard amino acid sequencing techniques can be used to determine the amino acid sequence of a purified P47PHOX polypeptide preparation. Alternatively, the nucleic acid encoding the polypeptide can be sequenced using standard nucleic acid sequencing techniques. Once the nucleic acid sequence is determined, the amino acid sequence of the encoded polypeptide can be deduced.

After determining at least a portion (e.g., about 10, 20, 30, 40, 50, 60, 70, 80, 90, or 100 percent) of the amino acid sequence of a polypeptide within the mammal's NADPH oxidase pathway, that amino acid sequence can be compared to the amino acid sequence of a comparable reference polypeptide that functions in the NADPH oxidase pathway such that at least about 70 percent (e.g., at least about 75, 80, 85, 90, 95, or 99 percent) of maximal NADPH oxidase activity is observed. For example, the amino acid sequence of a mammal's P47PHOX polypeptide can be compared to the amino acid sequence of a P47PHOX polypeptide that allows a cell to exhibit at least about 70 percent of maximal NADPH oxidase activity. Likewise, the amino acid sequence of a mammal's GP91PHOX polypeptide can be compared to the amino acid sequence of a GP91PHOX polypeptide that allows a cell to exhibit at least about 70 percent of maximal NADPH oxidase activity.

The term "maximal NADPH oxidase activity" as used herein refers to the average maximum level of NADPH oxidase activity measured in cells from healthy members of a particular species. For example, in rats, the maximal NADPH oxidase activity when measuring superoxide release from about  $5 \times 10^6$  peritoneal neutrophils using cytochrome C reduction can be 0.15-0.25 absorbance (550 nm) units at about 1000 seconds following stimulation with PMA. The cells can be treated with activators other than PMA such as fMLP, agents that destabilize cell membranes (e.g., pristane, squalene, phytol, and hexadecane), and agents that bind cell surface receptors (e.g., galectin1 and galectin 3). Since cells from E3 rats exhibit at least about 70 percent of this activity, the amino acid sequences of polypeptides that function in the NADPH oxidase pathway of the E3 rat can be used as reference polypeptides. For example, a rat's amino acid sequence of a P47PHOX polypeptide can be compared to the amino acid sequence of the P47PHOX



polypeptide of E3 rats, which is set forth in SEQ ID NO:4. In humans, the maximal NADPH oxidase activity when measuring superoxide release from about  $1 \times 10^6$  granulocytes using cytochrome C reduction can be 0.3 to 0.4 absorbance (550 nm) units about 7 minutes following stimulation with  $0.01 \mu\text{M}$  of fMLP. Thus, polypeptides that  
5 function in the NADPH oxidase pathway of human cells that exhibit at least 70 percent of that activity can be used as reference polypeptides. When assessing a human's P47PHOX polypeptide, the human P47PHOX polypeptide having the amino acid sequence set forth in SEQ ID NO:6 can be used as a reference polypeptide.

If the mammal being tested contains a mutant polypeptide when compared to a  
10 comparable reference polypeptide, then that mammal can be classified as being susceptible to developing arthritis. The mutant polypeptide can be a polypeptide that contains amino acid additions, subtractions, substitutions, or combinations thereof when compared to the sequence of a comparable reference polypeptide. For example, a mutant polypeptide can be a polypeptide having any number of amino acid differences (e.g., 1, 2,  
15 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 125, 150, 175, 200, or more amino acid additions, subtractions, or substitutions) when compared to a comparable reference polypeptide. Thus, in one embodiment, a human can be classified as being susceptible to developing arthritis if that human contains a P47PHOX polypeptide having an amino acid sequence with one or more (e.g., 2, 3, 4, 5, 6, 7, 8, 9,  
20 10, 11, 12, 13, 14, 15, or more) amino acid substitutions when compared to the amino acid sequence set forth in SEQ ID NO:6. Alternatively, a human can be classified as being susceptible to developing arthritis if that human contains a P47PHOX polypeptide having an amino acid sequence with an amino acid residue other than valine at the position that aligns with position 106 of SEQ ID NO:4.

25 In addition, a mutant polypeptide can be a polypeptide lacking one or more phosphorylation sites. Typically, phosphorylation sites are serine, threonine, or tyrosine residues. Thus, a polypeptide lacking one or more serine, threonine, or tyrosine residues when compared to a comparable reference polypeptide can be a mutant polypeptide. In one embodiment, a human can be classified as being susceptibility to develop arthritis if  
30 that human contains a P47PHOX polypeptide having an amino acid sequence lacking one or more (e.g., more than 2, 3, 4, 5, 6, 7, 8, 9, or 10) of the serine, threonine, or tyrosine

residues when compared to the amino acid sequence set forth in SEQ ID NO:6.

Alternatively, a human can be classified as being susceptible to developing arthritis if that human contains a P47PHOX polypeptide having an amino acid sequence with an amino acid residue other than threonine at the position that aligns with position 153 of SEQ ID

5 NO:4.

In addition to using the presence of a mutant polypeptide to determine whether or not a particular mammal is susceptible to arthritis, the regulatory sequences (e.g., promoters, enhancers, and silencers) that control the expression of a polypeptide that functions in the NADPH oxidase pathway can be examined. For example, the promoter  
10 sequences that control P47PHOX polypeptide expression can be compared to those promoter sequences that drive normal P47PHOX polypeptide expression in healthy humans. In this case, a human having a mutated regulatory promoter sequence can be classified as being susceptible to developing arthritis.

## 15 2. Diagnosing Mammals Having AANOD

The invention provides methods for determining whether a mammal has a particular type of arthritis. Specifically, a mammal can be diagnosed as having AANOD if that mammal has (1) clinical symptoms of arthritis and (2) cells having a level of NADPH oxidase activity that is either lower than a control value or impaired. In  
20 addition, a mammal can be diagnosed as having AANOD if that mammal has (1) clinical symptoms of arthritis and (2) a polypeptide that functions in the NADPH oxidase pathway and that contains a mutation when compared to a comparable reference polypeptide as described herein.

Clinical symptoms of arthritis include, without limitation, inflammation of  
25 tendons, ligaments, joints, or bones. Symptoms of arthritis also include pain, swelling, and stiffness in the limbs that can lead to weakness, loss of mobility, and deformity in the mammal. Examples of arthritis include, without limitation, bacterial arthritis, osteoarthritis, rheumatoid arthritis (RA), collagen-induced arthritis (CIA), hexadecane-induced arthritis (HIA), pristane-induced arthritis (PIA), avridine-induced arthritis,  
30 adjuvant induced arthritis, squalene-induced arthritis (SIA), and oil-induced arthritis (OIA).

The level of NADPH oxidase activity within a mammal's cells can be assessed as described herein. Likewise, the methods and materials described herein can be used to determine whether or not a mammal contains a mutant polypeptide that functions in the NADPH oxidase pathway.

5

### 3. *Treating arthritis*

The invention provides methods and materials for treating arthritis (e.g., AANOD) in a mammal. Methods for treating arthritis such as AANOD include administering an agent that increases the level of NADPH oxidase activity in the mammal. For example,  
10 an agent that increases a cell's production of reactive oxygen species can be administered to a mammal with arthritis. Such agents include, without limitation, norfloxacin, phosphatidic acid, diacylglycerol, arachidonic acid, phorbol myristate acetate, lysophosphatidylcholine, fMLP, octane, decane, undecane, dodecane, tridecane, tetradecane, hexadecane, heptadecane, octadecane; agents that destabilize cell membranes  
15 (e.g., pristane, squalene, phytol, and hexadecane), and agents that bind cell surface receptors (e.g., galectin1 and galectin 3). Alternatively, the agent can be a more polar derivative of the afore-mentioned compounds. For example, the agent can be an alkene derivative of the afore-mentioned compounds (e.g., undecene, hexadecene), or an acid derivative of the afore-mentioned compounds. In one embodiment, hexadecene is used.  
20 In another embodiment, undecane is used.

Agents that increase NADPH oxidase activity can be administered in any standard form using any standard method. For example, agents that increase NADPH oxidase activity can be in the form of tablets or capsules (e.g., time-release capsules) that are taken orally. Alternatively, the agents can be in a liquid form and can be taken orally or  
25 by injection. The agents also can be in the form of suppositories. Further, agents that increase NADPH oxidase activity can be in the form of creams, gels, and foams that can be applied to the skin. In addition, the agents can in the form of an inhalant that is applied nasally. The agent may be administered intra-dermally, intra-peritoneally, or intra-nasally.

30 Agents that increase NADPH oxidase activity can be administered at any dose that is sufficient to increase NADPH oxidase activity in cells that have low activity. Such

doses can be taken over a period of years to prevent and/or delay the progression arthritis or to reverse the progression of arthritis. Doses can be selected based on the effectiveness and toxicity of the particular agent using standard pharmacology techniques.

5    4. *Identifying Agent That Modify NADPH Oxidase Activity*

The invention provides methods and materials for identifying agents that modulate NADPH oxidase activity. Agents that modulate NADPH oxidase activity can increase or decrease NADPH oxidase activity. Examples of agents that increase NADPH oxidase activity include, without limitation, norfloxacin, phosphatidic acid, diacylglycerol, 10    arachidonic acid, phorbol myristate acetate, lysophosphatidylcholine, fMLP, octane, decane, undecane, dodecane, tridecane, tetradecane, hexadecane, heptadecane, octadecane; agents that destabilize cell membranes (e.g., pristane, squalene, phytol, and hexadecane), and agents that bind cell surface receptors (e.g., galectin1 and galectin 3). Examples of agents that decrease NADPH oxidase activity include, without limitation, 15    diphenylene iodonium, phenols, apocynin, quinone, haem ligands, piroxicam, B220 (2,3-dimethyl-6(2-dimethylaminoethyl)-6H-indolo-(2,3-b)quinoxaline), lidocaine, gliotoxin, hydrocortisone, OPC-6535 (6-[2-(3,4-diethoxyphenyl)thiazol-4-yl]-pyridine-2-carboxylic acid), and cromolyn.

To identify agents that increase or decrease NADPH oxidase activity, a test agent 20    can be mixed with a sample containing cells or cellular fractions having NADPH oxidase activity. Such cells can be from humans (e.g., healthy humans or arthritis patients) or non-human animals (e.g., healthy non-human animals or non-human animals susceptible to arthritis such as those susceptible to arthritis induction.) An animal is susceptible to arthritis induction if that animal develops an arthritis condition in response to treatment 25    with an inducing agent (e.g., collagen or pristane). Such animals include those susceptible to CIA, PIA, HIA, SIA, and OIA. The non-human animal can be any type of animal including, without limitation, monkeys (e.g., chimpanzees), horses, goats, cows, pigs, and rodents (e.g., mice and rats).

An example of a non-human animal that is susceptible to arthritis is a rat that is 30    susceptible to PIA such as the DA rat. A rat can be identified as a member of the DA strain (or any strain of interest) using standard methods. For example, standard nucleic

acid sequencing techniques can be used to compare genomic or mitochondrial nucleic acid sequences including, without limitation, (1) microsatellite sequences, (2) nucleic acid sequences encoding major histocompatibility complexes, or (3) nucleic acid sequences encoding 18S ribosomal RNA. Comparing nucleic acid sequence from two animals can be accomplished using genetic analysis tools such as restriction fragment length polymorphism-(RFLP) based methods and random amplified polymorphic DNA-(RAPD) based methods. Two animals can be concluded to be of the same strain if the nucleic acid sequences of both animals have similar characteristics when analyzed by RFLP or RAPD.

After being treated with the test agent, the level of NADPH oxidase activity can be determined. The sample can be any type of sample containing a cell or a cellular fraction having NADPH oxidase activity. The sample can be blood, lymph, or synovial fluid. The cell can be a lymphocyte, granulocyte (e.g., neutrophil) or macrophage.

The NADPH oxidase activity determined in the presence of a test agent can be compared with the NADPH oxidase activity determined in the absence of the test agent. Agents that increase NADPH oxidase activity are those that lead to an increase in NADPH oxidase activity by any amount (e.g., a 5, 10, 20, 30, 40, 50, 75, 100, 125, 150, 200, or more percent increase) when compared with the level of NADPH oxidase activity observed in the absence of the test agent. Agents that decrease NADPH oxidase activity are those that lead to a decrease in NADPH oxidase activity by any amount (e.g., a 5, 10, 20, 30, 40, 50, 75, or more percent decrease) when compared with the level of NADPH oxidase activity observed in the absence of the test agent.

In another embodiment, agents that increase or decrease NADPH oxidase activity can be identified in an assay mixture that includes NADPH oxidase, an activator, and a test agent. In these embodiments, NADPH oxidase activity, determined in the presence of an activator and a test agent, can be compared with the NADPH oxidase activity determined in the presence of the activator without the test agent. As described herein, agents that increase NADPH oxidase activity are those that, when present in the NADPH oxidase assay mixture, lead to an increase in NADPH oxidase activity by any amount (e.g., a 5, 10, 20, 30, 40, 50, 75, 100, 125, 150, 200, or more percent increase) when compared with the level of NADPH oxidase activity observed in the absence of the test

agent, while agents that decrease NADPH oxidase activity are those that, when present in the NADPH oxidase assay mixture, lead to a decrease in NADPH oxidase activity by any amount (e.g., a 5, 10, 20, 30, 40, 50, 75, or more percent decrease) when compared with the level of NADPH oxidase activity observed in the absence of the test agent.

5

#### *5. Non-DA Rats Containing Heterologous T-cells*

The invention provides methods and materials for generating an animal (e.g., a rodent such as a rat or mouse) that has heterologous T-cells in combination with a new form of inducible arthritis (i.e., T-cell induced arthritis; TIA). TIA can be generated in an animal by introducing into the recipient animal, T-cells from a donor animal that has arthritis. The donor and recipient animals can be from different strains or can be members of the same inbred group of animals that differ only with respect to (1) the QTL that contributes to arthritic susceptibility such as the *Pia4* QTL or (2) the sequence of the *p47phox* gene. T-cells can be isolated from an animal using any standard procedures including spleen homogenization. T-cell transfer can be performed using any conventional procedure. An animal with TIA can be used as described herein to identify agents that modify NADPH oxidase activity.

#### *6. Nonhuman mammals having deficient NADPH oxidase pathways*

Another aspect of the invention features methods and materials for providing a nonhuman mammal having a deficient NADPH oxidase pathway, where the nonhuman mammal exhibits symptoms of an autoimmune disease. The mammal may be a monkey, goat, horse, cow, pig, dog, cat, mouse, or rat. The autoimmune disease may be arthritis, multiple sclerosis, lupus, autoimmune uveitis, type I diabetes, bronchial asthma, septic arthritis induced with staphylococci or streptococci, or cardiovascular disease involving vasculitis. For example, the nonhuman mammal may exhibit symptoms of arthritis. The arthritis may be induced by standard techniques known in the art and may be, e.g., adjuvant induced arthritis, CIA, PIA, HIA, avridine induced arthritis, SIA, or OIA.

The deficient NADPH oxidase pathway in the nonhuman mammal may be indicated by a reduced NADPH oxidase activity. The reduced NADPH oxidase activity may be a result of a mutant polypeptide where the mutant polypeptide functions in the NADPH oxidase pathway. For example, the mutant polypeptide may be a GP91PHOX

polypeptide, P22PHOX polypeptide, P40PHOX polypeptide, P47PHOX polypeptide, or P67PHOX polypeptide. For example, the mutant polypeptide can be a P47PHOX polypeptide. The mutant P47PHOX polypeptide can contain the sequence set forth in SEQ ID NO:6 with at least two amino acid substitutions. The mutant P47PHOX

5 polypeptide can contain an amino acid sequence having an amino acid residue other than valine at the position that aligns with position 106 of SEQ ID NO:4 or an amino acid residue other than threonine at the position that aligns with position 153 of SEQ ID NO:4. In other embodiments, the reduced NADPH oxidase activity may be a result of a deletion of the gene or locus encoding Ncf1 (*p47phox*). The deletion may be heterozygous or

10 homozygous in the nonhuman mammal. In one embodiment, the nonhuman mammal may be a mouse. For example, the mouse may have the gene for Ncf1 (*p47phox*) knocked out using standard techniques in the art, or the mouse may express one of the mutant P47PHOX polypeptides as described previously (e.g., as a transgenic mouse).

15 *7. Screening of agents that delay, treat, or prevent arthritis*

In another embodiment, the invention provides a method of screening an agent to determine if the agent delays the onset of arthritis. The method includes: (a) providing a nonhuman mammal having a deficient NADPH oxidase pathway; (b) administering to the nonhuman mammal the agent; (c) inducing arthritis in the nonhuman mammal; and

20 (d) determining if the agent delays the onset of arthritis in the nonhuman mammal.

The mammal having a deficient NADPH oxidase pathway may be obtained as described previously. Determining if the agent delays the onset of arthritis may include steps such as: (a) determining a day of onset of arthritis value for the nonhuman mammal; and (b) comparing the day of onset of arthritis value for said nonhuman

25 mammal with a control day of onset of arthritis value. Onset of arthritis can be monitored using a macroscopic scoring system, wherein 1 point is given for each swollen or red toe, 1 point for each swollen midfoot, digit, or knuckle, and 5 points for a swollen ankle, yielding a maximum score of 15 per limb and 60 total. The score can be a mean score, additive score, or maximum score. The mammal may be monitored 1 to 4 times a week

30 for 1 to 2 months after induction of arthritis. The control day of onset of arthritis value may be determined by determining a day of onset of arthritis value for a control

nonhuman mammal to which the agent has not been administered. The day of onset of arthritis in the nonhuman mammal may be considered delayed if it is later than the control day of onset value. The arthritis may be induced by conventional means and can be adjuvant induced arthritis, CIA, PIA, HIA, SIA, avridine induced arthritis, or OIA.

5           The invention also provides methods to screen an agent to determine if the agent treats arthritis. The method includes (a) providing a nonhuman mammal having a deficient NADPH oxidase pathway, where the nonhuman mammal exhibits symptoms of an arthritis (e.g., adjuvant induced arthritis, CIA, PIA, HIA, SIA, avridine induced arthritis, or OIA); (b) administering to the nonhuman mammal the agent; and (c)  
10       determining if the agent treats arthritis in the nonhuman mammal. Such a determining step may involve (a) calculating an arthritis score in the nonhuman mammal; and (b) comparing the arthritis score with a control arthritis score. The mammal having a deficient NADPH oxidase pathway exhibiting symptoms of arthritis may be obtained as described previously. The control arthritis score may be determined by calculating an  
15       arthritis score for a control nonhuman mammal to which the agent has not been administered. The arthritis score may be determined using the macroscopic scoring system described previously, and may be a mean score, additive score, or maximum score. The agent may be determined to treat arthritis if the arthritis score in the nonhuman animal is less than the control arthritis score.

20           In another embodiment, a method of screening an agent to determine if the agent prevents arthritis is provided. The method includes: (a) providing a nonhuman mammal having a deficient NADPH oxidase pathway; (b) administering to the nonhuman mammal the agent; (c) administering a compound known to induce arthritis to the nonhuman mammal; and (d) determining if the agent prevents arthritis induced by the  
25       compound in the nonhuman mammal. Determining if the agent prevents arthritis may include evaluating said nonhuman mammal for symptoms of arthritis. Such an evaluation may occur for a period of time, e.g., for up to 20 days, up to 30 days, up to 50 days, or up to 70 days. Determining if the agent prevents arthritis may include comparing any symptoms of arthritis and their day of onset with the symptoms and day of onset of a  
30       control nonhuman mammal to which said agent has not been administered. The macroscopic scoring system as described above may be used in the evaluation and



comparison. The compound known to induce arthritis may be an adjuvant, collagen, pristane, hexadecane, squalene, avridine, or oil. Collagen may be type II collagen; the oil may be incomplete Freund's adjuvant; and the adjuvant may be mycobacterial-derived.

The invention will be further described in the following examples, which do not  
5 limit the scope of the invention described in the claims.

## EXAMPLES

### Example 1 – Animals

Rat (*Rattus norvegicus*) strains used in the following experiments included the DA  
10 strain, which is highly susceptible to PIA, and the E3 strain, which is PIA-resistant. DA and E3 rats were obtained from Zentralinstitut für Versuchstierzucht, Hannover, Germany, and were kept in animal facilities that have climate-controlled environments with 12-hour light/dark cycles. Rats were housed in polystyrene cages containing wood shavings and were fed standard rodent chow and water *ad libitum*. Rats were free from common  
15 pathogens, including the Sendai virus, Hantaan virus, coronavirus, reovirus, cytomegalovirus, and *Mycoplasma pulmonis*. Animal breeding and experimentation were performed in the same animal facility.

### Example 2 - Induction and Evaluation of Arthritis

20 Arthritis was induced in rats at the age of 8 to 12 weeks by intradermal injections of 150 µL of pristane (2,6,10,14-tetramethylpentadecane; Aldrich, Milwaukee, WI) at the bases of the tails. Arthritic development was monitored in all limbs using a macroscopic scoring system. Briefly, 1 point was given for each swollen or red toe, 1 point for each swollen midfoot, digit, or knuckle, and 5 points for a swollen ankle. The maximum score  
25 for a limb was 15 points, and the maximum score for a rat was 60 points. Rats were examined from one to four times a week for one month after pristane injection.

For histopathologic analyses, at 31 days after pristane injections, rats were sacrificed, and the hind paws and ankle joints were prepared and analysed as follows. The paws were fixed in 4 % paraformaldehyde, decalcified in EDTA, embedded in

paraffin, and then sectioned and stained with hematoxylin and erythrosine as described in Jonsson *et al.* (1986) *J Immunol Methods* 88:109-14.

### Example 3 - Confirmation of Linkage to Arthritis Severity in Congenic Strains

5        A quantitative trait locus (QTL), denoted *Pia4*, was found to be associated with PIA and CIA. To identify and isolate genes in the *Pia4* QTL that are associated with arthritis, a 10 cM fragment of chromosome 12 from a PIA resistant E3 rat was introgressed into a PIA susceptible DA rat resulting in a DA.E3chr12 congenic rat. Other E3 genes on the 10 cM fragment that were not associated with RA were removed in  
10       greater than 10 successive backcrosses with a DA rat. DA littermate rats obtained from F2 intercrosses between DA.E3chr12 +/- rats were used as controls. The *Pia4* QTL was inherited in a DA additive fashion with DA rats having the arthritis severity promoting allele in the original F2 intercross between E3 and DA rats. Significant phenotypic differences observed when a progeny rat is compared to the control rat could be  
15       concluded to have arisen from genetic differences at the *Pia4* region.

      Arthritis was induced in 20 DA rats, 40 DA.E3chr12+/- rats, and 14 DA.E3chr12-/- rats by injection with pristane, and the development of clinical arthritis was assessed as described earlier. Figure 1 is a comparison of the clinical arthritis scores determined at day 10, 14, 19, 24, and 28 after pristane injections of DA rats, DA.E3chr12+/- rats, and  
20       DA.E3chr12-/- rats. Dramatic differences in arthritis severity were seen between DA littermate controls and DA.E3chr12 congenic rats ( $p < 0.0001$ ). The DA.E3chr12 -/- congenic rats were still susceptible to arthritis, but the inflammation was very mild. The incidences of arthritis observed at 31 days after pristane injections were 100 % among DA rats, 58 % among DA.E3+/- rats, and 36 % among DA.E3-/- rats. When sections of  
25       rat hind paw ankle joints obtained 31 days after pristane injections were stained with hematoxylin and erythrosine and then examined microscopically at 100 X magnification, cell infiltrations into the joints were observed. Although the PIA resistant E3 phenotype afforded by the *Pia4* QTL was found to be almost dominant protective, DA progeny rats carrying two E3 alleles of chromosome 12 exhibited even less severe arthritis ( $p < 0.05$ )  
30       than DA progeny rats carrying one E3 allele of chromosome 12.

The E3 derived fragment containing the *Pia4* QTL also was found to suppress CIA, HIA, and OIA (see Table 1). Other genes appear involved since E3 rats congenic for DA derived *Pia4*, (e.g. E3.DA chr12-/- rats) were still resistant to arthritis.

- 5 Table 1. Susceptibility of the *Pia4* congenic rat strain to CIA, OIA, and HIA. The P-value indicates the significance of the difference observed between *Pia4* congenic rats and DA rats. No significant difference between DA.E3chr12 +/- and DA.E3chr12 -/- was detected.

	Number of rats studied	Arthritis types	Maxscore	p-value
DA	10	OIA	15.1 ± 4.7	
DA.E3chr12 +/-	15	OIA	4.5 ± 1.6	<0.05
DA.E3chr12 -/-	15	OIA	1.2 ± 0.7	<0.05
DA	13	CIA	50.3 ± 3.4	
DA.E3chr12 +/-	16	CIA	29.8 ± 4.8	<0.01
DA.E3chr12 -/-	7	CIA	29.4 ± 6.0	<0.01
DA	9	HIA	14.6 ± 2.5	
DA.E3chr12 +/-	8	HIA	3.9 ± 2.4	<0.05

10 Example 4 - Sequencing and Physical Mapping

- The P1-derived artificial chromosome (PAC) library of the BN rat (RPCI-31) described in Woon *et al.* (1998) *Genomics* 50:306-16 was obtained from the Resource Center of the German Human Genome Project (RZPD) (see world wide web at rzpd.de) as DNA pools and arrayed filters (library 712). Positive PAC clones also were obtained from RZPD as well as clones that have DNA inserts corresponding to DNA in the vicinity of *Pia4* linked microsatellites (see Gosele *et al.* (2000) *Genomics* 69:287-94, world wide web at mdc-berlin.de/ratgenom, and world wide web at world wide web at
- 15

molgen.mpg.de/~ratgenome). PAC clones were purified using the Qiagen Large Construction Kit (Qiagen, Hilden, Germany) and used for end sequencing with T7 and SP6 primers as described in Woon et al. (1998) Genomics 50:306-16.

5 The rat *p47phox*, *GTF2i*, and *GTF2ird* cDNA sequences were determined as follows. Publicly available sequences corresponding to rat *p47phox* (GenBank Accession number AY029167), mouse *GTF2i* (GenBank Accession number AF017085) and mouse *GTF2ird* (GenBank Accession number NM\_020331) sequences were used for primer design. E3, DA, and DA.E3chr12 RNAs were isolated using RNeasy Mini Kit (Qiagen, Hilden, Germany). First strand cDNAs were synthesized from total RNA using the First-  
10 strand cDNA Synthesis Kit (Amersham Pharmacia Biotech, Uppsala, Sweden). Double stranded cDNA fragments were generated by conventional PCR and then ligated into the pCR4-TOPO TA cloning vector. The resulting plasmid constructs were transformed into competent *E. coli* (Invitrogen, Paisley, UK), and then purified from *E. coli* transformants according to conventional alkaline lysis purification. Sequencing was performed using  
15 the MegaBACE 1000 (Amersham Pharmacia Biotech, Uppsala, Sweden) sequencer and the data obtained were analysed using Sequence Analysis 2.1 and SeqMan 4.05.

#### Example 5 - Genotyping and Statistic Analysis

DNA was prepared from toe biopsies and assayed with microsatellite markers by  
20 polymerase chain reaction (PCR) analysed on MegaBACE 1000 (Amersham Pharmacia Biotech, Uppsala, Sweden). Quantitative data were expressed as mean  $\pm$  SEM, and significance analysis was performed using nonparametric Mann-Whitney test. Significance of frequency data was determined by Chi-square analyses.

#### 25 Example 6 – Results of Physical Mapping and Positional Cloning

To identify genes within the *Pia4* QTL that contribute to the PIA resistant phenotype in E3 rats, DA.E3chr12 congenic rats were backcrossed with DA rats, and a large number of congenic progeny rats carrying overlapping *Pia4* fragments of different sizes was used in the following experiment. Physical mapping was initiated with a  
30 congenic fragment of 1 cM. Figure 2 is a physical map of the *Pia4* region constructed using PAC clones and EST clones. Known microsatellites (d12rat72, d12got45,

d12got46 and d12rat26) in the *Pia4* region were used to identify PAC carrying inserts corresponding to this region. Results of the Rat EST project at the University of Iowa (see world wide web at ratEST.uiowa.edu) were used to identify EST clones known to contain sequences in the *Pia4* region. The end sequences of the PAC clones and primer  
5 sequences from EST clones were used in generating the physical map of the *Pia4* region. In addition, sequence information from the *Pia4* region in rat (PAC clones RP31-78c13, RP31-485f9, RP31-198i13, RP31-75g22, RP31-11m22, RP31-391d23 RP31-57j23), from the partially sequenced BAC clones having inserts corresponding to the *Pia4* region (see world wide web at hgsc.bcm.tmc.edu/projects/rat/), and sequences from homologous  
10 regions in mouse (Genbank Accession numbers NT\_029829, AF289665, AF139987 and AF267747; see Kwitek *et al.* (2001) *Genome Res* 11:1935-43; Hoogenraad *et al.* (1998) *Genomics* 53:348-58; Valero *et al.* (2000) *Genomics* 69:1-13) and human (Genbank accession number NT\_007867; see Peoples *et al.* (2000) *Am J Hum Genet* 66:47-68; Osborne *et al.* (2001) *Nat Genet* 29:321-5) were assembled to form the *Pia4* physical  
15 map.

The physical map of the *Pia4* region in combination with the arthritis susceptibility of isolated congenic strains identified a minimal region of 300 kilobases required for the PIA resistant phenotype. The 300 kilobase region contained two genes: *p47phox* and *GTF2i*. The *p47phox* gene encodes Neutrophil Cytosolic Factor 1 (NCF1),  
20 a subunit of the NADPH complex that produces oxygen radicals as a result of infection (see Volpp *et al.* (1989) *Proc Natl Acad Sci U S A* 86:7195-9). The *GTF2i* gene encodes Bruton Tyrosine Kinase (BTK)-Associated Protein (BAP-135), a substrate of BTK involved in the B-cell receptor-signalling pathway, see Yang & Desiderio (1997) *Proc Natl Acad Sci U S A* 94:604-9.

25

#### Example 7 – The *p47phox* E3 Allele has a Dominant Protective Role in Arthritis

Single nucleotide polymorphisms (SNPs) that distinguish the DA and E3 alleles in the *Pia4* region were identified by sequencing cDNA using the Pyrosequencing (Pyrosequencing, Uppsala, Sweden) according to protocols supplied by the manufacturer.  
30 SNPs were found in the *p47phox*, *GTF2i*, *GTF2ird1* and *Cyln2* (AJ000485) genes.

A comparison of the DA *p47phox* cDNA and the E3 *p47phox* cDNA revealed three SNPs (see Figure 3). All three polymorphisms were base substitutions of which two were non-synonymous and resulted in substitutions at amino acid positions 106 and 153. These sequence polymorphisms included (1) substitution of an adenine with a guanine nucleotide at position 330 in an E3 rat when compared a DA rat (DA/E3; A330G) resulting in replacement of a methionine residue with a valine residue at position 106 (Met106Val); (2) substitution of a thymine with a cytosine nucleotide at position 472 in an E3 rat (DA/E3; T472C) resulting in replacement of a methionine residue with a threonine residue at position 153 (Met153Thr); and (3) substitution of an adenine with a cytosine at nucleotide 1161, a synonymous substitution that did not lead to an amino acid alteration. The sequence of the *p47phox* cDNA from the DA rat was identical to the published sequence of *p47phox* (AY029167) from Sprague-Dawley rat.

A comparison of the DA *GTF2i* cDNA sequence with the E3 *GTF2i* sequence revealed that the E3 sequence had a nucleotide substitution at position 2992. The thymine nucleotide at position 2992 in the DA sequence was substituted with a cytosine nucleotide in the E3 sequence (DA/E3; T2992C). This substitution occurred in the untranslated region and so did not affect the *GTF2i* protein sequence.

Similar comparisons of the *Cyln2* and *GTF2ird1* genes of DA and E3 rats revealed SNPs at nucleotide 4206 (DA/E3: G4206A) in the *Cyln2* gene and at nucleotide 2823 (DA/E3: G2823C) in the *GTF2ird1* gene.

#### Example 8 - Prevalence of the *p47phox* Polymorphisms in Inbred and Wild Rats

The sequences of *p47phox* genes in other inbred rat strains and in wild rats were analysed for the presence of the three polymorphisms in the *p47phox* E3 allele (Table 2). High degrees of polymorphisms in inbred rats as well as in wild rats were detected. This suggests that these polymorphisms did not result from domestication or from mutations generated in inbred laboratory rats. In fact, the DA and E3 alleles occurred in equal frequency indicating that these alleles were maintained by natural selection.

Table 2. Polymorphisms in the *p47phox* gene identified in DA/E3 inbred rat and wild rat populations.

Rat strain	SNP 330bp	SNP 472bp	SNP 1161bp	Rat strain	SNP 330bp	SNP 472bp	SNP 1161bp
DA	DA	DA	DA	SPRD-Cu3	DA	E3	DA
E3	E3	E3	E3	WAG-rnu	E3	E3	DA
ACI	E3	E3	E3	WC	E3	E3	DA
BDE	E3	E3	DA	WF	DA	DA	DA
BDII	E3	E3	DA	WKY	DA	DA	DA
BDIX	E3	E3	DA	KL-1	E3	E3	DA/E3
BDV	DA	DA	DA	KL-2	E3	DA/E3	DA/E3
BH	DA	E3	DA	KL-3	DA	DA	DA
BN	DA	E3	DA	KL-4	DA	DA	DA
BS	DA	E3	DA	KL-5	-	E3	-
COP	E3	E3	E3	KL-6	DA/E3	DA/E3	DA
DA-rnu	DA	DA	DA	KL-7	DA/E3	DA	DA
DXEA	E3	E3	E3	KL-8	DA/E3	DA	DA
DXEB	DA	DA	DA	KL-9	E3	DA	DA
DXEC	DA	DA	DA	KL-10	DA	DA	DA
DXER	DA	E3	DA	KL-11	E3	DA	E3
F344	DA	DA	DA	KL-12	DA	E3	-
GK	DA	DA	DA	KL-13	DA/E3	DA/E3	DA
LE	DA	DA	DA	KL-14	E3	DA	DA
LEW	DA	DA	DA	KL-15	E3	DA	DA
Lew (BM)	E3	E3	E3	KL-16	E3	DA	DA/E3
Lewis.1F	DA	DA	DA	KL-17	E3	DA	DA/E3
LOU7C	E3	E3	E3	KL-18	E3	DA	DA
LXB10	DA	DA	DA	JH-1	DA/E3	DA	DA/E3
LXB17L	DA	DA	DA	JH-2	DA	DA/E3	DA
LXB17N	DA	DA	DA	JH-3	DA	E3	DA
LXB19	DA	E3	DA	JH-4	DA	E3	DA
LXB21	DA	DA	DA	Ax-1	E3	DA	E3
LXB22	DA	DA	DA				
LXB24	DA	E3	DA				
LXB26	DA	E3	DA				
LXB27	DA	E3	DA				
LXB3	DA	E3	DA				
LXB30	DA	E3	DA				
LXB8	DA	DA	DA				
MNS	DA	E3	DA				
MWF	E3	E3	DA				
NAR	E3	E3	DA				
NEDH	DA	DA	DA				
NZNU	E3	E3	E3				
OM	DA	DA	DA				
PVG	E3	E3	E3				
RNU-rnu	E3	E3	E3				
SHR	E3	E3	E3				
SPRD	DA	DA/E3	DA				

A common haplotype present in BN rats included the DA polymorphism at nucleotide 330 and the E3 polymorphism at nucleotide position 472. Previously published crosses between DA and BN rats exhibiting disease conditions similar to multiple sclerosis (see Dahlman *et al.* (1999) *J Immunol* 162:2581-8) or arthritis (see Griffiths *et al.* (2000) *Arthritis Rheum* 43:1278-89) revealed a locus with identical location as *Pia4* suggesting that disease protection is associated with threonine at amino acid 153. Since threonine is a potential phosphorylation site, and since the function of the human NADPH complex is highly regulated through phosphorylation of *p47phox*, it is likely that activity of P47PHOX and therefore activity of NADPH oxidase is affected by the phosphorylation state of this residue. (See Faust *et al.* (1995) *J Clin Invest* 96:1499-505; El Benna *et al.* (1996) *J Biol Chem* 271:6374-8; Lal *et al.* (1999) *Biochem J* 338:359-66).

#### Example 9 - DA and DA.E3chr12 -/- Congenic Rats Exhibited Similar *p47phox*

##### Expression Levels

Expression of the *p47phox* gene in the spleens and lymph node tissues of DA and DA.E3chr12 rats was analysed by Northern blot hybridisation. Three DA and three DA.E3chr12/- rats were subjected to pristane injection. Eight days after pristane injections, 10 µg of total RNA from the spleen and inguinal lymph node were isolated. RNA was separated on an agarose/formaldehyde gel, transferred onto nylon membrane, and fixed by ultraviolet irradiation. The resulting Northern blot was subjected to hybridization with two probes: (1)  $\alpha^{32}\text{P}$ -dCTP labeled DNA encoding rat P47PHOX and (2)  $\alpha^{32}\text{P}$ -dCTP labeled DNA encoding 36B4-ribosomal protein. Hybridization was performed overnight at 42°C in Ambion ULTRA hybridization buffer (Ambion, Austin Texas). After hybridization, the Northern blot was washed according to the manufacturer's instructions, and then subjected to phosphor imaging using the Kodak screen and Imager FX system (Bio-Rad, Hercules CA, USA). A probe directed against acidic ribosomal protein (Z29530) was used as the control for the total amount of RNA analysed.

No difference in the expression level of *p47phox* mRNA was detected when DA and DA.E3chr12 -/- congenic rats were compared. Therefore, polymorphisms in the



*p47phox* gene rather than differences in the expression level of *p47phox* accounted for the difference in arthritis severity.

Polypeptide expression of p47phox was analyzed by western blot. Spleen cells were lysed for 2 hours at 4°C in lysis buffer (3x10<sup>7</sup> cells/100 µL), 150 mM NaCl, 1 mM CaCl<sub>2</sub>, 1 mM MgCl<sub>2</sub>, 20 mM Tris pH 7.4, 0.5% triton X-100 (Sigma), 0.25 M sucrose, protease inhibitor tablet (Roche Diagnostics), and 10 µg/mL deoxyribonuclease I (Sigma), and centrifuged at 14000 rpm. Equivalent amounts of total protein in the supernatant, determined by a protein assay kit (BioRad), were subjected to SDS-PAGE using a 10% separation gel. The polypeptides were electrophoretically transferred to a nitrocellulose membrane (Biorad). The membranes were incubated with polyclonal rabbit antibodies to the Ncfl peptide RRS TIR NAQ SIH QRC, biotinylated donkey anti-rabbit IgG (Jackson ImmunoResearch Laboratories), and ExtrAvidin peroxidase conjugate (Sigma). Immunoreactive polypeptide bands were visualized using enhanced chemoluminescence, ECL, reagents, and Hyperfilm (Amersham Pharmacia Biotech).

No difference in polypeptide expression between DA and DA.E3chr12 -/- rats was observed.

#### Example 10 - Plasma Levels of COMP and $\alpha_1$ -AGP Were Lower in DA.E3chr12 Congenic Rats than in Control Rats

Cartilage oligomeric matrix protein (COMP) and  $\alpha_1$ -acid glycoprotein (AGP) are two plasma markers that are closely associated with RA as well as PIA. AGP, produced by hepatocytes, is a marker of general inflammatory response, while circulating COMP is the product of cartilage destruction and/or cartilage turnover. At 31 days after pristane injections, levels of AGP and COMP in the serum of DA, DA.E3chr12+/-, and DA.E3chr12-/- rats were determined as follows.

The serum level of AGP was measured in a competitive radioimmunoassay (RIA; see Akerstrom (1985) *J Biol Chem* 260:4839-44) using a rat  $\alpha_1$ -acid glycoprotein (Zivic-Miller Laboratories, Zelienople, PA) and a polyclonal anti-rabbit antibody specific for rat  $\alpha_1$ -acid glycoprotein (Agrisera, Vännäs, Sweden).

Plasma concentration of COMP was determined by enzyme linked inhibition immunosorbent assay (ELISA) as described in Saxne & Heinegard (1992) *Br J Rheumatol* 31:583-91. Rat COMP was used for coating microtiter plates and for preparing standard curves. Plasma COMP was detected using a polyclonal antiserum generated against rat COMP as the capturing antibody. The polyclonal antiserum was obtained from professor Dick Heinegård.

Figures 4A and 4B are bar graphs demonstrating that plasma levels of COMP and AGP in DA.E3chr12 congenic rats were significantly lower than plasma levels of COMP and AGP in DA controls ( $p < 0.005$ ).

Example 11 - Oxidative Burst Assay Demonstrating That the Arthritis Severity-Promoting Variant of the *p47phox* Gene in DA Rats is Linked to Decreased Oxidative Burst

The function of P47PHOX was examined by assessing production of reactive oxygen species (ROS) by peritoneal neutrophils. Rats were injected intraperitoneally with 5 mL of 2.4 % thioglycollate to elicit recruitment of neutrophils. Sixteen hours after thioglycollate injections, rats were sacrificed, and neutrophils were isolated from the peritoneal cavities as follows. The peritoneal cavities were rinsed with Hank's balanced salt solution (HBS), and the cells obtained were washed twice with HBS and then resuspended at a concentration of  $10^7$  cells/mL.

The activity of the NADPH complex as indicated by production of ROS was determined by spectrophotometric detection of cytochrome C reduction (see Lomax *et al.* (1989) *Science* 245:409-12; Huang *et al.* (2000) *J Leukoc Biol* 67:210-5; and Zu *et al.* (1996) *Blood* 87:5287-96). Briefly,  $5 \times 10^6$  cells were dispensed into each well of a 96 well microtitre plate containing 100  $\mu$ g of cytochrome C (Sigma C3131) yielding a total volume 100  $\mu$ L. Activation of NADPH complexes and secretion of superoxide radicals were initiated upon addition of PMA (Sigma P8139) to a concentration of 0.1  $\mu$ g/mL. Reactions occurred at 37°C, and the absorbance at 550 nm was measured at 1-minute intervals.

Figure 5A-D is a set of absorbance curves illustrating production of ROS by DA rats, E3 rats, and *Pia4* congenic rats (DA.E3c12+/- and DA.E3c12-/- rats). Production of

oxygen radicals was determined from determining the area under the curve. These results demonstrate that the production of ROS is higher in E3 and *Pia4* congenic rats than in DA littermates. About three to six rats were examined in each genotypic group.

Unlike human patients with autosomal chronic granulomatous disease (CGD) (see 5 Casimir *et al.* (1991) *Proc Natl Acad Sci U S A* 88:2753-7) or mice deficient in functional *p47phox* (see Jackson *et al.* (1995) *J Exp Med* 182:751-8; and Huang *et al.* (2000) *J Leukoc Biol* 67:210-5), DA rats were not completely lacking in functional NADPH complexes or ROS production. While E3 rats and DA.E3chr12 congenic rats exhibited maximum cytochrome C reduction ( $OD_{550} = 0.2$ ) 1000 seconds after PMA stimulation, 10 levels of ROS production in DA rats were slower and did not attain maximum cytochrome C reduction even after 3000 seconds. Therefore, the arthritis severity-promoting variant of the *p47phox* gene in DA rats is linked to decreased oxidative burst.

#### Example 12 – NADPH Inhibition in DA.E3chr12 Rats

The following experiment was performed to determine if the protective effect of 15 the *Pia4* QTL is accounted for by the presence of polymorphisms in the *p47phox* gene leading to decreased free radical production from NADPH complexes.

DA and DA.E3chr12 rats were given diphenyleneiodonium chloride (DPI,  $C_{12}H_8ICl$ , MW = 314.6), a potent inhibitor of nitric oxide synthase (NOS) and flavoenzymes such as NADPH oxidase. DPI had been used *in vivo* in mice to inhibit 20 potassium peroxochromate-induced arthritis (see, Miesel *et al.*, (1996) *Free Radic Biol Med* 20:75-81). Daily intraperitoneally administration of 2.8  $\mu\text{mol/kg}$  weight of a mouse (i.e., 880  $\mu\text{g/kg}$ ) was found to reduced arthritis by 50 percent.

In this experiment, DPI was administered at a dosage of 1.25  $\mu\text{mol DPI/kg}$  weight of a rat (i.e., 0.4 mg/kg weight of a rat). Assuming that each rat had a mean weight of 25 225 g, about 0.08 mg of DPI in 0.5 mL of DMSO/PBS was given to each rat. For administration, 50 mg of DPI was dissolved in 250 mL DMSO/PBS. About 0.5 mL was injected intraperitoneally into rats on day 0, 2, 3, 4, 5, 6, 7, 8, 10, 12, 14, 17, 19, and 21.

Arthritis was induced in all rats at the age of 8 to 12 weeks by intradermal injections of 150  $\mu\text{L}$  of pristane at the bases of the tails. Arthritis development was 30 monitored in all limbs. Results presented in Figure 6 and 7 reveal that inhibition of

NADPH oxidase with DPI lead to increased severity of arthritis. Therefore, NADPH oxidase activity has a protective role in development of PIA.

Example 13 - Transfer of ConA Activated T-cells from a DA Rat Induced

Arthritis in E3 Rats and DA.E3chr12 Congenic Rats

To determine if the *Pia4* QTL controls the priming of arthritogenic T-cells or is involved in events that occur subsequent to the onset of arthritis, reciprocal spleen T-cell transfer experiments were performed using DA littermate controls, DA.E3chr12 +/- rats, and DA.E3chr12 -/- rats as donors or recipients of spleen cells activated with the T-cell mitogen ConA. Three rats from each group were used as donors, and three rats from each group were used as recipients.

Donor rats were injected with 500  $\mu$ L of pristane. Twelve days after injections, rats were sacrificed, and their spleens were removed and homogenized for spleen T-cell isolation. Spleen cells were activated with ConA prior to transfer to recipient rats.

Briefly, spleen T-cells were activated by culturing them at a cell density of  $4 \times 10^6$  cells/mL for 48 hours at 37°C in DMEM medium (Paisley Scotland), supplemented with streptomycin, D-penicillin, HEPES,  $\beta$ -mercaptoethanol, 5 % fetal calf serum, and 3  $\mu$ g/mL Con A. Spleen cells were then harvested, resuspended in PBS, and injected intraperitoneally into recipient rats at a concentration of  $35 \times 10^6$  cells/animal.

Arthritis onset was detected at day 5 after T-cell transfer, and the highest arthritis scoring was obtained at day 15. Figure 8 is a bar graph illustrating that transfer of ConA activated T-cells from a DA rat gave rise to severe arthritis in E3 rats, in DA.E3chr12 +/- rats, and in DA.E3chr12 -/- rats. In addition, only ConA activated T-cells from a DA rat were arthritogenic. Therefore, the *p47phox* polymorphisms are involved in the generation of arthritogenic T-cells, but do not appear to operate significantly in the joints since the DA.E3chr12 congenic rats were susceptible to arthritis when subjected to DA T-cell transfers. Since P47PHOX functions in the spleen before T cell transfer, it is likely that, through its role in generating ROS, P47PHOX affects T-cell/antigen presenting cell interaction in the lymphoid organs.

#### Example 14 – Evaluation of Alkanes as NADPH Oxidase

##### Activators in the Oxidative Burst Assay

Saturated alkanes molecules C8-C19 (n-octane, nonane, undecane, dodecane, tridecane, tetradecane, pentadecane, hexadecane, heptadecane, octadecane, and nonadecane) were tested for their ability to activate the NADPH complex as described below. The unsaturated fatty acids C14:1-C24:1 (myristoleic acid, palmitoleic acid, oleic acid, linoleic acid, linolenic acid, 11c-eicosenoic acid, arachidonic acid, erucic acid, and neuronc acid) and squalenee (Sigma) were also tested. The oils were solubilized by dilution in cyclodextrin (100 mM in PBS).

##### *Isolation of peritoneal neutrophils and macrophages:*

5 mL thioglycolate (2.4%) was injected intraperitoneally in E3 rats to elicit recruitment of neutrophils 16 hours before sacrifice. 40 mL PBS+hapes (1%) was injected into the peritoneum and the cell suspension extracted. Red blood cells were lysed with 0.84% NH<sub>4</sub>Cl, and WBC were washed in PBS and resuspended in PBS at a concentration of about 10<sup>7</sup> cells/mL.

##### *Culture of peritoneal neutrophils and macrophages:*

Human myeloma cell line HL60 was cultured in Dulbeccos complete medium with Hepes, 10% Fetal calf serum, and Penicillin–Streptomycin. HL60 cells differentiated to neutrophil-macrophages six days after addition of 1.25% DMSO. The cells were spun down at 1200 rpm for 5 minutes and then washed with PBS twice. The cells were then resuspended in PBS to a concentration of about 10<sup>7</sup> cells/mL.

##### *Oxygen burst analysis through WST-1 assay:*

10 µL of each of the oils to be tested was added with 9 µL of WST1 to the wells of a 96 well microtitre plate. 10<sup>6</sup> cells/mL (100 µL of 10<sup>7</sup> cells/mL) were added to each well and the color change measured in a spectrophotometer at 450 nm at 37° for 60 minutes (one measurement/min).

*Cytochrome C assay:*

10  $\mu\text{L}$  each of the oils to be tested were added to the wells of a 96 well microtitre plate. 50  $\mu\text{L}$  of cytochrome C (4 mg/mL) and  $5 \times 10^6$  cells/well (50  $\mu\text{L}$  of  $10^7$  cells/mL) were added to each well and the absorbance measured in a spectrophotometer at 550 nm  
5 at 37°C for 60 minutes (one measurement/minute).

*FACS based burst assay:*

Cells ( $2-5 \times 10^5$  well) are preincubated for 10 minutes at 37°C with 1  $\mu\text{M}$  dihydrorhodamine (DHR) 123 in a 96 well plate in total volume of 200  $\mu\text{L}$ . 10  $\mu\text{L}$  each of  
10 the compounds (e.g., oils) to be tested are added to the wells and incubated a further 20 minutes at 37°C. Production of reactive oxidants is assayed as formation of the fluorescent dye rhodamine 123 (RH) from dihydrorhodamine 123 (DHR) using flow cytometry.

15 *Results*

Saturated alkane molecules were tested with the oxidative burst assay to determine activators of the NADPH complex. The assays were tested in both peritoneal cells from E3 rat after thioglycolate recruitment of neutrophils (Figure 9A) and HL60 cells (Figure 9B). The WST-1 test indicates changes in the extracellular concentration of  
20 reactive oxygen species (ROS). Both cell types demonstrates the same general trends. For example, in all assays, undecane was a potent activator.

The arthritis-inducing effects of the oils was examined by injecting the oils intradermally into DA rats. The scoring shows that oils more than about 14 carbons long induce arthritis, while shorter carbon chains do not induce arthritis (Figures 10A, 10B,  
25 and 10C). Note that  $p < 0.05$  for alkanes shorter than C15 compared to C19. All statistics evaluated with student's t-test. N=4 for all groups.

Example 15 - Prevention and Ameliorative Treatment of Arthritis  
with NADPH-Activating Oils

*1. Treatment and/or prevention of pristane-induced arthritis with undecane in vivo.*

5           Groups of DA rats were injected intradermally at the base of the tail with 200  $\mu$ L of the oils as indicated below:

Undecane day -10, Pristane day 0;

Olive oil day -10, Pristane day 0;

Undecane day -5, Pristane day 0;

10           Undecanol day -5, Pristane day 0;

Olive oil day -5, Pristane day 0;

Undecane day 5, Pristane day 0; and

Olive oil day 5, Pristane day 0.

15           The rats were scored every other day starting at day 11 according to the extended scoring system where every red or swollen toe or mid foot scored one point, and a red and swollen ankle scored five points, yielding a total of 15 points/limb and 60 points/rat. Olive oil and undecanol were used as controls.

*2. In vivo treatment of Hexadecane-induced arthritis with hexadecene*

20           Groups of DA rats were injected i.d. at the base of the tail as follows:

Hexadecane 200  $\mu$ L day 0;

Hexadecene 200  $\mu$ L day 0;

Hexadecene 200  $\mu$ L day -5, Hexadecane 200  $\mu$ L day 0;

25           Olive oil 200  $\mu$ L day -5, Hexadecane 200  $\mu$ L day 0;

Hexadecene 200  $\mu$ L day +5, Hexadecane 200  $\mu$ L day 0; and

Olive oil day 200  $\mu$ L +5, Hexadecane 200  $\mu$ L day 0.

The rats were scored as indicated above. Olive oil was used as a control.

### Results

Undecane was examined for its potential preventive effect on the development or severity of PIA. Rats were treated with undecane on day -10, day -5, or day +5, and undecanol on day -5 (as a control). All rats were injected with pristane on day 0 (Figure 11A). There was a significant difference between both the additive score (Figure 11B) and the maximum score (Figure 11C) for rats treated with undecane on day -5 and the rats that were treated with olive oil on day -5. There was also a significant difference for both the additive score (Figure 11B) and the maximum score (Figure 11C) between the treatment with undecane on day -5 and the treatment with undecanol on day -5. Note also that the rats that were treated with undecane on day +5 had a slightly higher score than the rats that were treated with undecane on day -10 or day -5 before injection with pristane.

All statistics were evaluated with student's t-test.  $p < 0.05$  for the difference in both additive score and maximum score for undecane at day -5 and olive oil at day -5.  $p = 0.05$  for the difference in additive score and  $p < 0.05$  for the difference in maximum score between undecane at day -5 and undecanol at day -5.  $N = 6$  for all groups except group 4 where  $N = 12$ .

A similar experiment was also performed to evaluate the protective effect of hexadecene on arthritis-induction by hexadecane. Rats were treated with hexadecene either on day -5, day +5, or were not treated with hexadecene. All rats were injected with hexadecane on day 0, except group 3. Olive oil was used as control. The arthritis scores demonstrate a significant difference between the arthritis-inducing capacities of the two substances (Figures 12A, 12B and 12C). Hexadecane induces arthritis while hexadecene does not. The difference in scores between the rats that were treated with hexadecene on day -5 and day +5 and the control rats is also significant. None of the rats treated with hexadecene developed arthritis.

Groups 3 and 4 were injected only with either hexadecane or hexadecene. All statistics were evaluated with student's t-test.  $p < 0.05$  for the difference in both additive score and maximum score for treatment day -5 and day +5 against no treatment (group 4).  $p < 0.05$  for the difference in both additive score and maximum score between hexadecane and hexadecene. There is also a significant difference between the groups



that were injected with hexadecene and olive oil day +5 ( $p < 0.01$  in the additive score and  $p < 0.05$  in maximum score).  $N = 6$  for all groups except group 3 and 4 where  $N = 4$ .

### Discussion

When oils were injected into the base of the tails of DA rats to determine their arthritis - inducing capacities, alkanes longer than about 14 carbons induced arthritis, while shorter ones did not. It is interesting to note that a comparison of the activity of the oils in the oxygen burst studies and the arthritis induction studies indicates three possible mechanisms for participation of the oils in the induction and/or treatment of arthritis. For example, in the oxygen burst studies, undecane activated the NADPH complex, but did not induce arthritis in the tail-injection arthritis studies, while hexadecane not only activated the complex but also induced arthritis. A comparison of the two experiments demonstrates that the hexa-, hepta-, and octa-decanes activate the NADPH complex according to the WST-1 assay and also induce arthritis. Pentadecane (15C), on the other hand, did not activate the NADPH complex, but did induce arthritis, suggesting a third mechanism for participation in the induction of the disease.

A similar relationship has been seen with hexadecane and hexadecene, and pristane and phytol, where hexadecane and pristane induce arthritis, while hexadecene and phytol do not (Lorenzen (1999) *Scand. J. Immunol.* 49:45-50). All four substances activate the NADPH complex. The difference between hexadecane and hexadecene is a single carbon-carbon double-bond in hexadecene, while pristane and phytol differ by an acidic group. While not being bound by any theory, it is possible that an increased polarity facilitates the metabolism of the hexadecene and phytol, and therefore prevents them from inducing arthritis. Molecules with lower polarity cannot be metabolised as easily, and may remain longer in tissues, inducing an immune response.

We investigated the preventive capacities of both hexadecene and undecane. None of the rats treated with hexadecene showed any symptoms of arthritis whether they were injected with hexadecene at day -5 or day +5. Further, these experiments verify that hexadecane induces arthritis, while hexadecene does not. Pre-treatment with undecane may be more protective if done at a longer time point before induction of arthritis with pristane. For example, treatment with undecane at day +5 did not show as significant a preventive effect as at day -10 or at day -5.

### Example 16 - *In vivo* Distribution of Alkane Oils

[1-<sup>14</sup>C] - Hexadecane and [1-<sup>14</sup>C] - Oleic acid were purchased from Amersham. The oils were injected intradermally at the base of the tail in 18 DA rats (200  $\mu$ L). At day 10, the organs (lymph nodes, spleen, liver and kidney) of three rats from each group were collected. The organs were weighed and homogenized in a total volume of 2 mL PBS and frozen. The same procedure was followed at day 20 and at day 30. 1 mL of the homogenised samples was then added to 10 mL Ready Safe (Beckman) and counted in a beta counter. The distribution of radioactive labelled hexadecane to the lymph nodes was also inspected at earlier time points (day 3, day 6, day 10, and day 13).

#### *Results:*

The distribution of hexadecane *in vivo* was examined by injecting radioactively-labeled hexadecane i.d. at the base of the tail in DA rats. Radioactively-labeled oleic acid was administered in the same manner. Scoring of the rats showed that only the rats injected with hexadecane had arthritis (Figure 13). The arthritis was acute and had a symmetric involvement of both hind and front paws. Analyses of the different organs collected (LN, spleen, kidney and liver) in the  $\beta$ -counter showed that the oils were exclusively accumulated in the lymph nodes at all time points measured (Figure 14). Hexadecane seems to be distributed to the lymph nodes to a higher extent than oleic acid. The distribution of the oils to the lymph nodes appeared to decrease with time with no increase in the other organs analyzed.

The distribution of hexadecane to the lymph nodes at earlier time points was also measured as described. An increase in the accumulation of hexadecane in the lymph nodes until day 10 was observed.

The distribution of radioactively-labeled hexadecane had previously been investigated, showing that <sup>14</sup>C- labeled hexadecane is disseminated predominantly to the lymph nodes (Kleinau et al., (1995). *Int. J. Immunopharmac.*, 17(5):393-401.).

The experiments indicate that the hexadecane oil exerts a pro-arthritis effect within the lymph nodes. The injection of both radioactively- labeled hexadecane and radio-labeled oleic acid suggests that oleic acid does not induce arthritis because it is not distributed to the lymph nodes to as high an extent as the hexadecane. Furthermore,

hexadecane slowly accumulated in the lymph nodes with a maximum at day 10, correlating with the normal onset of the disease. After day 10, the concentration of the hexadecane oil slowly decreased (Figure 15).

5      Example 17 – Treatment of Experimental Allergic Encephalomyelitis (EAE) *in vivo*

Groups of DA rats were injected at the base of the tail with 200  $\mu$ L phytol at day – 10, day –5, and day +5. Olive oil was used as a control. At day 0, all rats were treated (immunized) with 200  $\mu$ L SCH (DA spinal cord homogenate, to induce EAE) i.d. at the base of the tail. The rats were then scored according to the following scale for 40 days:

- |    |   |
|----|---|
| 10 | 0=Normal  |
|    | 1=Tail weakness                                   |
|    | 2=Tail paralysis                                  |
|    | 3=Tail paralysis and mild waddle                  |
|    | 4=Tail paralysis and severe waddle                |
| 15 | 5=Tail paralysis and paralysis of one limb        |
|    | 6=Tail paralysis and paralysis of a pair of limbs |
|    | 7=Tetra-paresis                                   |
|    | 8=Pre-morbid or dead.                             |

EAE began to appear around day 9. The results show a significant difference in both additive score (Figure 16A) and maximum score (Figure 16B) between the rats treated with phytol and the control rats at day –10 and at day +5 ( $p < 0.05$ ).

All statistics were evaluated with students' T test.  $p < 0.05$  for the difference in maximum score between treatment with phytol and treatment with olive oil at day –10 and day +5. Note that N= 6 for all groups.

25      In both EAE and PIA, the SCH to induce EAE and the pristane to induce PIA were injected intradermally at the base of the tail. The disease onset generally occurred in a few weeks. Potential activators of the NADPH complex may alter the proliferation of auto reactive T-cells and reduce the incidence, rate of onset, and severity of the diseases.

Example 18 - Effect of Route of Administration of Phytol on Treatment of PIA

Groups of DA rats were treated with phytol according to one of the following treatment regimens at day -5 and at day +5. All rats were injected with pristane (200  $\mu$ L) at day 0 intradermally at the base of the tail. Phytol was administered to groups of rats as follows:

- 25  $\mu$ L phytol intranasally (i.n.);
- 200  $\mu$ L phytol intraperitoneally (i.p.);
- 200  $\mu$ L phytol intradermally at the base of the tail (i.d.); and
- 1 mL phytol per os (p.o.).

The rats were scored from day 9 using the extended scoring system (as discussed previously).

The experiment demonstrated an ameliorating and preventive effect of i.d. administration. Intraperitoneal (i.p.) and intranasal (i.n.) routes of administration also demonstrated ameliorative and preventive effects. (See Figures 17A, 17B and 17C).

Note that the intranasal group was skewed by one rat that exhibited severe arthritis, while the three other rats in the group were protected.

Example 19 - Collagen Induced Arthritis in Ncf1-deficient Mice*Animals*

Mice (B6.Cg-m +/+ Lepr (db), formerly known as C57BL/6J-m +/+ Lepr<sup>db</sup>) deficient for Ncf1 because of a point mutation in the splice site for exon 8 (Huang et al., (2000) *J. Leukoc. Biol.* 67:210-215.) were purchased from the Jackson Laboratory (Maine, USA). The mice were backcrossed to B10.Q (originally from Professor Jan Klein, Tübingen, Germany) for two generations to yield the Q haplotype in MHC and to lose the leptin receptor (lepr) defect. B10.Q Ncf1 +/- were intercrossed for the Collagen Induced Arthritis (CIA) experiments in order to obtain littermate control animals. All arthritis experiments were approved by local (Malmö/Lund, Sweden) ethical committee license M7-01.

*Induction and evaluation of arthritis*

Arthritis was induced in all mice at the age of 9-15 weeks by an intradermal injection at the base of the tail of 150 µg rat CII (collagen II) emulsified in complete Freund's adjuvant (CFA; Difco, Detroit, MI) at day 0. At day 35, the mice were given a  
5 booster injection at the same location of 50 µg rat CII in Freund's incomplete adjuvant (IFA). Arthritis development was monitored in all four limbs using a macroscopic scoring system. Briefly, 1 point was given for each swollen or red toe, 1 point for each swollen midfoot, digit, or knuckle, and 5 points for a swollen ankle, yielding a maximum score per limb of 15 and 60 total. The mice were examined 1 to 4 times a week for 2  
10 months after immunization. At day 40, serum was obtained through tail bleeding and kept at -20° C until assayed.

*Determination of serum levels of COMP*

Serum concentration of cartilage oligomeric matrix protein (COMP) was  
15 determined using an enzyme linked inhibition immunosorbent assay (ELISA). Rat COMP was used to coat the microtitre plates and to prepare the standard curve for each plate. Plasma COMP was detected by using a polyclonal antiserum raised against rat COMP (generously provided by Professor Dick Heinegård) as capturing antibody.

*Antibody response*

Antibodies against rat cartilage in plasma were analysed with ELISA in 96 well plates (Costar, Cambridge, MA), coated overnight at 4°C with 50 µL/well of PBS containing 10 µg/mL of rat collagen II. All washings were performed using Tris-buffered saline (NaCl 1.3M, Tris 0.1M, pH 7.4) containing 0.1% Tween20 (Tris/Tween). The  
25 plasma was diluted in PBS/0.1% Tween and analyzed in duplicate. The amounts of bound IgG antibodies were estimated after incubation with a donkey anti-mouse IgG coupled to peroxidase (Jackson ImmunoResearch, Westgrove, PA) and ABTS as substrate, followed by detection in a SpectraMax (Molecular Devices). The relative amount of antibodies in plasma was determined by comparison with a positive control of an anti collagen II  
30 standard.

### Results

In order to determine the role of defects or deficiencies of functional Ncf1 and/or the NADPH oxidase complex on arthritis, the development of CIA (collagen induced arthritis) in Ncf1 deficient B10.Q mice was investigated. Wild type B10.Q mice normally develop a mild/medium-severe arthritis, with onset after booster immunization (Svensson et al. (1998) *Clin. Exp. Immunol.* 111:521-526). The results indicate both an earlier onset (Figure 19) and increased severity of arthritis ( $P < 0.001$ ) (Figures 18A, 18B, 18C) in Ncf1 deficient mice as compared to B10.Q mice. Mice heterozygous for the defect Ncf1 showed a milder arthritis with later onset than the homozygous deficient mice ( $P < 0.005$ ).

The quantification of serum levels of COMP (Cartilage Oligomeric Matrix Protein) is regarded as a measurement of the cartilage erosion of peripheral joints. Serum COMP was highly elevated ( $P < 0.0001$ ) in the Ncf1  $-/-$  mice as compared to Ncf1  $+/-$  and wild type controls (Figure 20). Furthermore, in the Ncf1 deficient mice there was a strong antibody response against collagen II at day 40 after the first immunization (Figure 21).

#### Example 20 - Distribution in the Lymph Nodes of 14C-hexadecane After Injection of Hexadecene at day -5

An experiment was performed to determine if oils compete for available space in the lymph nodes and if such a competition was the reason for the preventive effects of pre-treatment with hexadecene and undecane. At day -5, DA rats were injected with one of the following amounts of hexadecene: 0  $\mu\text{L}$ , 50  $\mu\text{L}$ , 100  $\mu\text{L}$ , or 200  $\mu\text{L}$ . At day 0, all rats were injected intradermally with 14C-hexadecane at the base of the tail. At day 10, the rats were sacrificed and the lymph nodes were collected and placed in PBS, homogenized, and frozen. 1 mL of the homogenate was then transferred to Ready Safe (Beckman) and analysed in a  $\beta$ -counter (Beckman).

The amount of arthritis inducing hexadecane in draining lymph nodes was not affected by larger amounts of protective hexadecene. These results indicate that there is no competition for space in the draining lymph nodes that is of importance for the protective effect of the oil.

Example 21 - CIA in rats treated with phytol

DA rats were treated according to one of the following alternatives:

200  $\mu$ L phytol intra-dermal at the base of the tail at day -10

200  $\mu$ L phytol intra-dermal at the base of the tail at day -5

5 200  $\mu$ L phytol intra-peritoneal at day -5 and day +5

control untreated

CIA was induced in all animals at day 0 by injecting 150  $\mu$ L of collagen II dissolved in 75  $\mu$ L 0.1 M Acetic acid and emulsified in 75  $\mu$ L IFA. The rats were scored from day 10 using the extended scoring system (see above).

10 Both intra-peritoneal and intra-dermal treatment with phytol prevented development of arthritis in the CIA rat model (Figure 22).

Example 22 - Treatment of active PIA with phytol or undecane

Groups of DA rats were injected with pristane at day 0. The pristane (150  $\mu$ L) was injected intra-dermal at the base of the tail. The rats were scored from day 9 using the extended scoring system (see above). Then, the rats were treated at day 21 and at day 26 with one of the following alternatives:

200  $\mu$ L phytol intra-peritoneal

200  $\mu$ L phytol intra-dermal at the base of the tail

20 200  $\mu$ L undecane intra-peritoneal

200  $\mu$ L undecane intra-dermal at the base of the tail

control untreated

All the phytol and undecane treatments were effective against active arthritis in the PIA rat model (Figures 23A, 23B).

25

**OTHER EMBODIMENTS**

It is to be understood that while the invention has been described in conjunction with the detailed description thereof, the foregoing description is intended to illustrate and not limit the scope of the invention, which is defined by the scope of the appended claims.

30 Other aspects, advantages, and modifications are within the scope of the following claims.

**WHAT IS CLAIMED IS:**

1. A method for assessing a mammal's susceptibility to develop an autoimmune condition, said method comprising:
  - 5 (a) providing a blood or synovial fluid sample containing a cell from a mammal;
  - (b) determining the level of NADPH oxidase activity of said cell after contacting said cell with an NADPH oxidase activator;
  - (c) determining whether or not said level is less than a control level of NADPH oxidase activity, wherein said control level is the average amount of NADPH oxidase activity of control cells from a population of mammals without said autoimmune condition, and wherein said mammals without said autoimmune condition are from the same species as said mammal; and
  - 10 (d) identifying said mammal as being susceptible to develop said autoimmune condition when said level is less than said control level.
- 15 2. The method of claim 1, wherein said autoimmune condition is arthritis or multiple sclerosis.
3. The method of claim 1, wherein said NADPH oxidase activator is norfloxacin, phosphatidic acid, diacylglycerol, arachidonic acid, phorbol myristate acetate, lysophosphatidylcholine, fMLP, pristane, phytol, octane, decane, undecane, dodecane, tridecane, tetradecane, hexadecane, hexadecene, heptadecane, octadecane, galectin 1, or galectin 3.
- 20 4. The method of claim 1, wherein said level of NADPH oxidase activity is determined by measuring superoxide.
5. The method of claim 1, wherein said level of NADPH oxidase activity is determined by measuring reactive oxygen species.
- 30 6. The method of claim 1, wherein said population comprises at least ten mammals.



7. The method of claim 1, wherein step (c) comprises determining whether or not said level is between 5 and 75 percent less than said control level, and wherein step (d) comprises identifying said mammal as being susceptible to develop said autoimmune condition when said level is between 5 and 75 percent less than said control level.
8. The method of claim 1, wherein step (c) comprises determining whether or not said level is between 25 and 55 percent less than said control level, and wherein step (d) comprises identifying said mammal as being susceptible to develop said autoimmune condition when said level is between 25 and 55 percent less than said control level.
9. A method for assessing a mammal's susceptibility to develop an autoimmune condition, said method comprising:
- (a) providing a blood or synovial fluid sample from a mammal;
  - (b) determining the level of a blood or synovial fluid component that reflects NADPH oxidase activity;
  - (c) determining whether or not said level is less than a control level, wherein said control level is the average amount of said component in control samples from a population of mammals without said autoimmune condition, and wherein said mammals without said autoimmune condition are from the same species as said mammal; and
  - (d) identifying said mammal as being susceptible to develop said autoimmune condition when said level is less than said control level.
10. The method of claim 9, wherein said autoimmune condition is arthritis or multiple sclerosis.
11. The method of claim 9, wherein said component that reflects NADPH oxidase activity is malonic dialdehyde.
12. A method for assessing a mammal's susceptibility to develop an autoimmune condition, said method comprising determining whether or not a mammal comprises a

genetic variant of the gene encoding a polypeptide that functions in the NADPH oxidase pathway, wherein the presence of said genetic variant indicates that said mammal is susceptible to develop said autoimmune condition.

5 13. The method of claim 12, wherein said autoimmune condition is arthritis or multiple sclerosis.

14. The method of claim 12, wherein said genetic variant encodes a mutant polypeptide.

10

15. The method of claim 14, wherein said mutant polypeptide is a GP91PHOX polypeptide, P22PHOX polypeptide, P40PHOX polypeptide, P47PHOX polypeptide, or P67PHOX polypeptide.

15 16. The method of claim 14, wherein said mutant polypeptide is a P47PHOX polypeptide.

17. The method of claim 16, wherein said mammal is a human, and wherein said mutant P47PHOX polypeptide comprises the sequence set forth in SEQ ID NO:6 with at  
20 least two amino acid substitutions.

18. The method of claim 16, wherein said mutant P47PHOX polypeptide comprises an amino acid sequence having an amino acid residue other than valine at the position that aligns with position 106 of SEQ ID NO:4 or an amino acid residue other than  
25 threonine at the position that aligns with position 153 of SEQ ID NO:4.

19. The method of claim 12, wherein said genetic variant comprises a mutation in a regulatory sequence of said gene.

20. A method for diagnosing an autoimmune condition accompanied by NADPH oxidase deficiency in a mammal having an autoimmune condition, said method comprising:
- (a) providing a sample comprising a cell from said mammal;
  - 5 (b) determining the level of NADPH oxidase activity of said cell after contacting said cell with an NADPH oxidase activator;
  - (c) determining whether or not said level is less than a control level of NADPH oxidase activity, wherein said control level is the average amount of NADPH oxidase activity of control cells from a population of mammals without said autoimmune
  - 10 condition, and wherein said mammals without said autoimmune condition are from the same species as said mammal; and
  - (d) identifying said mammal as having said autoimmune condition accompanied by NADPH oxidase deficiency when said level is less than said control level.
- 15 21. The method of claim 20, wherein said autoimmune condition is arthritis or multiple sclerosis.
22. The method of claim 20, wherein said autoimmune condition accompanied by NADPH oxidase deficiency is AANOD.
- 20 23. The method of claim 20, wherein said NADPH oxidase activator is norfloxacin, phosphatidic acid, diacylglycerol, arachidonic acid, phorbol myristate acetate, lysophosphatidylcholine, fMLP, pristane, phytol, octane, decane, undecane, dodecane, tridecane, tetradecane, hexadecane, hexadecene, heptadecane, octadecane, galectin 1, or
- 25 galectin 3.
24. The method of claim 20, wherein said level of NADPH oxidase activity is determined by measuring superoxide.
- 30 25. The method of claim 20, wherein said level of NADPH oxidase activity is determined by measuring reactive oxygen species.

26. The method of claim 20, wherein said population comprises at least ten mammals without said autoimmune condition.

27. The method of claim 20, wherein step (c) comprises determining whether or not said level is between 5 and 75 percent less than said control level, and wherein step (d) comprises identifying said mammal as having said autoimmune condition accompanied by NADPH oxidase deficiency when said level is between 5 and 75 percent less than said control level.

28. The method of claim 20, wherein step (c) comprises determining whether or not said level is between 25 and 55 percent less than said control level, and wherein step (d) comprises identifying said mammal as having said autoimmune condition accompanied by NADPH oxidase deficiency when said level is between 25 and 55 percent less than said control level.

29. A method for diagnosing an autoimmune condition accompanied by NADPH oxidase deficiency in a mammal having an autoimmune condition, said method comprising:

- (a) providing a blood or synovial fluid sample from said mammal;
- (b) determining the level of a blood or synovial fluid component that reflects NADPH oxidase activity;
- (c) determining whether or not said level is less than a control level of NADPH oxidase activity, wherein said control level is the average amount of NADPH oxidase activity of control cells from a population of mammals without said autoimmune condition, and wherein said mammals without said autoimmune condition are from the same species as said mammal; and
- (d) identifying said mammal as having said autoimmune condition accompanied by NADPH oxidase deficiency when said level is less than said control level.

30. The method of claim 29, wherein said autoimmune condition is arthritis or multiple sclerosis.
31. The method of claim 29, wherein said autoimmune condition accompanied by  
5 NADPH oxidase deficiency is AANOD.
32. The method of claim 29, wherein said component that reflects NADPH oxidase activity is malonic dialdehyde.
- 10 33. A method for diagnosing an autoimmune condition accompanied by NADPH oxidase deficiency in a mammal having an autoimmune condition, said method comprising determining whether or not said mammal comprises a genetic variant of the gene encoding a polypeptide that functions in the NADPH oxidase pathway, wherein the presence of said genetic variant indicates that said mammal has said autoimmune  
15 condition accompanied by NADPH oxidase deficiency.
34. The method of claim 33, wherein said autoimmune condition is arthritis or multiple sclerosis.
- 20 35. The method of claim 33, wherein said autoimmune condition accompanied by NADPH oxidase deficiency is AANOD.
36. The method of claim 33, wherein said genetic variant encodes a mutant polypeptide.  
25
37. The method of claim 36, wherein said mutant polypeptide is a GP91PHOX polypeptide, P22PHOX polypeptide, P40PHOX polypeptide, P47PHOX polypeptide, or P67PHOX polypeptide.
- 30 38. The method of claim 36, wherein said mutant polypeptide is a P47PHOX polypeptide.

39. The method of claim 38, wherein said mammal is a human, and wherein said mutant P47PHOX polypeptide comprises the sequence set forth in SEQ ID NO:6 with at least two amino acid substitutions.
- 5
40. The method of claim 38, wherein said mutant P47PHOX polypeptide comprises an amino acid sequence having an amino acid residue other than valine at the position that aligns with position 106 of SEQ ID NO:4 or an amino acid residue other than threonine at the position that aligns with position 153 of SEQ ID NO:4.
- 10
41. The method of claim 33, wherein said genetic variant comprises a mutation in a regulatory sequence of said gene.
42. A method for treating a mammal having an autoimmune condition accompanied by NADPH oxidase deficiency, said method comprising administering, to said animal, an agent that enhances NADPH oxidase activity.
- 15
43. The method of claim 42, wherein said autoimmune condition is arthritis or multiple sclerosis.
- 20
44. The method of claim 42, wherein said autoimmune condition accompanied by NADPH oxidase deficiency is AANOD.
45. The method of claim 42, wherein said agent is norfloxacin, phosphatidic acid, diacylglycerol, arachidonic acid, phorbol myristate acetate, lysophosphatidylcholine, fMLP, pristane, phytol, octane, decane, undecane, dodecane, tridecane, tetradecane, hexadecane, heptadecane, octadecane, galectin 1, or galectin 3.
- 25
46. The method of claim 42, wherein said agent is polar derivative of norfloxacin, phosphatidic acid, diacylglycerol, arachidonic acid, phorbol myristate acetate,
- 30

lysophosphatidylcholine, fMLP, pristane, phytol, octane, decane, undecane, dodecane, tridecane, tetradecane, hexadecane, heptadecane, octadecane, galectin 1, or galectin 3.

47. The method of claim 42, wherein said agent is an alkene or acid derivative of  
5 norfloxacin, phosphatidic acid, diacylglycerol, arachidonic acid, phorbol myristate acetate, lysophosphatidylcholine, fMLP, pristane, phytol, octane, decane, undecane, dodecane, tridecane, tetradecane, hexadecane, heptadecane, octadecane, galectin 1, or galectin 3.

10 48. The method of claim 42, wherein said agent is administered intra-dermally, intra-peritoneally, or intra-nasally.

49. The use of an agent in the manufacture of a medicament to treat an autoimmune condition accompanied by NADPH oxidase deficiency, wherein said agent enhances  
15 NADPH oxidase activity in a mammal.

50. The use of claim 49, wherein said autoimmune condition accompanied by NADPH oxidase deficiency is AANOD.

20 51. The use of claim 49, wherein said autoimmune condition accompanied by NADPH oxidase deficiency is multiple sclerosis accompanied by NADPH oxidase deficiency.

52. The use of claim 49, wherein said agent is norfloxacin, phosphatidic acid,  
25 diacylglycerol, arachidonic acid, phorbol myristate acetate, lysophosphatidylcholine, fMLP, pristane, phytol, octane, decane, undecane, dodecane, tridecane, tetradecane, hexadecane, hexadecene, heptadecane, octadecane, galectin 1, or galectin 3.

53. A method of formulating a medicament for the treatment of an autoimmune  
30 condition, said method comprising:

(a) contacting a sample comprising cells or a cellular fraction having NADPH activity with a test agent,

(b) determining the level of NADPH oxidase activity in said sample,

(c) determining whether or not said level is greater than a control level of NADPH oxidase activity, wherein said control level is the amount of NADPH oxidase activity in a control sample lacking said test agent,

(d) identifying said test agent as an agent useful for treatment of said autoimmune condition when said level of NADPH oxidase activity is greater than said control level, and

(e) formulating a medicament from said agent for the treatment of said autoimmune condition.

54. The method of claim 53, wherein said autoimmune condition is arthritis or multiple sclerosis.

15

55. A method for identifying an agent that activates NADPH oxidase activity in a cell, wherein said cell is from a non-human animal susceptible to arthritis induction, said method comprising determining whether or not the level of NADPH oxidase activity increases in said cell after said cell is treated with a test agent, wherein an increase in said level indicates that said test agent activates NADPH oxidase activity.

20

56. The method of claim 55, wherein said cell is a cell from a DA rat.

57. The method of claim 55, wherein said cell is a lymphocyte.

25

58. The method of claim 55, wherein said non-human animal is susceptible to pristane induced arthritis, collagen induced arthritis, adjuvant induced arthritis, oil induced arthritis, hexadecane induced arthritis, or avaridine induced arthritis.

59. The method of claim 55, wherein said level of NADPH oxidase activity is determined by measuring superoxide.

30



60. The method of claim 55, wherein said level of NADPH oxidase activity is determined by measuring reactive oxygen species.

5 61. The method of claim 55, wherein said level of NADPH oxidase activity is determined with a cytochrome C assay or WST-1 assay.

62. A method for identifying an agent useful in the treatment of an autoimmune condition, said method comprising:

- 10 (a) contacting a sample comprising cells or a cellular fraction having NADPH activity with a test agent,
- (b) determining the level of NADPH oxidase activity in said sample,
- (c) determining whether or not said level is greater than a control level of NADPH oxidase activity, wherein said control level is the amount of NADPH oxidase activity in a
- 15 control sample lacking said test agent, and
- (d) identifying said test agent as an agent useful for treatment of said autoimmune condition when said level of NADPH oxidase activity is greater than said control level.

63. The method of claim 62, wherein said autoimmune condition is arthritis or

20 multiple sclerosis.

64. A method for identifying an agent useful in the treatment of an autoimmune condition, said method comprising:

- 25 (a) contacting a sample comprising cells or a cellular fraction having NADPH activity with a test agent,
- (b) contacting said sample with an NADPH oxidase activator,
- (c) determining the level of NADPH oxidase activity in said sample,
- (d) determining whether or not said level is greater than a control level of NADPH oxidase activity, wherein said control level is the amount of NADPH oxidase activity in a
- 30 control sample treated with said activator in the absence of said test agent, and

(e) identifying said test agent as an agent useful for treatment of said autoimmune condition when said level of NADPH oxidase activity is greater than said control level.

65. The method of claim 64, wherein said autoimmune condition is arthritis or  
5 multiple sclerosis.

66. A method for identifying an agent that enhances NADPH oxidase activity in a cell, wherein said cell is from a non-human animal susceptible to arthritis induction, said method comprising:

- 10 (a) contacting said cell with an NADPH oxidase activator and a test agent to form a test cell,
- (b) determining the level of NADPH oxidase activity in said test cell,
- (c) determining whether or not said level is greater than a control level of NADPH oxidase activity, wherein said control level is the amount of NADPH oxidase  
15 activity in a control cell treated with said activator in the absence of said test agent, and
- (d) identifying said agent as enhancing NADPH oxidase activity when said level is greater than said control level.

67. The method of claim 66, wherein said cell is a cell from a DA rat.  
20

68. The method of claim 66, wherein said cell is a lymphocyte.

69. The method of claim 66, wherein said non-human animal is susceptible to pristane induced arthritis, collagen induced arthritis, adjuvant induced arthritis, oil induced  
25 arthritis, hexadecane induced arthritis, or avidine induced arthritis.

70. The method of claim 66, wherein said NADPH oxidase activator is norfloxacin, phosphatidic acid, diacylglycerol, arachidonic acid, phorbol myristate acetate, lysophosphatidylcholine, fMLP, pristane, phytol, octane, decane, undecane, dodecane,  
30 tridecane, tetradecane, hexadecane, heptadecane, octadecane, galectin 1, or galectin 3.

71. The method of claim 66, wherein said level of NADPH oxidase activity is determined by measuring superoxide.
72. The method of claim 66, wherein said level of NADPH oxidase activity is  
5 determined by measuring reactive oxygen species.
73. The method of claim 66, wherein said level of NADPH oxidase activity is determined with a cytochrome C assay or WST-1 assay.
- 10 74. A method for identifying an agent that inhibits NADPH oxidase activity in a cell, wherein said cell is from a non-human animal susceptible to arthritis induction, said method comprising:
- (a) contacting said cell with an NADPH oxidase activator and a test agent to form a test cell,
  - 15 (b) determining the level of NADPH oxidase activity in said test cell,
  - (c) determining whether or not said level is less than a control level of NADPH oxidase activity, wherein said control level is the amount of NADPH oxidase activity in a control cell treated with said activator in the absence of said test agent, and
  - (d) identifying said agent as inhibiting NADPH oxidase activity when said level  
20 is less than said control level.
75. The method of claim 74, wherein said cell is a cell from a DA rat.
76. The method of claim 74, wherein said cell is a lymphocyte.  
25
77. The method of claim 74, wherein said non-human animal is susceptible to pristane induced arthritis, collagen induced arthritis, adjuvant induced arthritis, oil induced arthritis, hexadecane induced arthritis, or avridine induced arthritis.
- 30 78. The method of claim 74, wherein said NADPH oxidase activator is norfloxacin, phosphatidic acid, diacylglycerol, arachidonic acid, phorbol myristate acetate,

lysophosphatidylcholine, fMLP, pristane, phytol, octane, decane, undecane, dodecane, tridecane, tetradecane, hexadecane, heptadecane, octadecane, galectin 1, or galectin 3.

79. The method of claim 74, wherein said level of NADPH oxidase activity is  
5 determined by measuring superoxide.

80. The method of claim 74, wherein said level of NADPH oxidase activity is determined by measuring reactive oxygen species.

10 81. A method for identifying an agent that modulates T-cell activation, said method comprising:

(a) determining whether or not a test agent increases NADPH oxidase activity;

and

(b) classifying said test agent as an agent that modulates T-cell activation when  
15 said test agent increases NADPH oxidase activity.

82. The method of claim 81, wherein said modulation of T-cell activation is a reduction in T-cell activation.

20 83. A rat congenic to a second rat, wherein at least one locus differs genetically between said rat and said second rat, wherein said second rat is susceptible to arthritis induction, wherein said rat contains T-cells from said second rat, and wherein said rat has arthritis.

25 84. The rat of claim 83, wherein said rat is a DA.E3c12-/- rat.

85. The rat of claim 83, wherein said second rat is a DA rat.

86. The rat of claim 83, wherein said at least one locus comprises nucleic acid that  
30 encodes a P47PHOX polypeptide.

87. The rat of claim 83, wherein no more than one locus differs genetically between said rat and said second rat.
88. The rat of claim 87, wherein said one locus comprises nucleic acid that encodes a P47PHOX polypeptide.
89. A nonhuman mammal comprising a deficient NADPH oxidase pathway, wherein said nonhuman mammal exhibits symptoms of an autoimmune disease.
90. A method of screening an agent to determine if said agent delays the onset of arthritis, said method comprising:
- (a) providing a nonhuman mammal having a deficient NADPH oxidase pathway;
  - (b) administering said agent to said nonhuman mammal;
  - (c) inducing arthritis in said nonhuman mammal; and
  - (d) determining if said agent delays the onset of arthritis in said nonhuman mammal.
91. A method for screening an agent to determine if said agent treats arthritis, said method comprising:
- (a) providing a nonhuman mammal having a deficient NADPH oxidase pathway, wherein said nonhuman mammal exhibits symptoms of an arthritis;
  - (b) administering to said nonhuman mammal said agent; and
  - (c) determining if said agent treats arthritis in said nonhuman mammal.
92. A method of screening an agent to determine if said agent prevents arthritis, wherein said method comprises:
- (a) providing a nonhuman mammal having a deficient NADPH oxidase pathway;
  - (b) administering to said nonhuman mammal said agent;
  - (c) administering a compound that induces arthritis to said nonhuman mammal;
- and

(d) determining if said agent prevents arthritis induced by said compound in said nonhuman mammal.

93. A method for identifying an agent that inhibits NADPH oxidase activity in a lymphocyte, wherein said lymphocyte is from a DA rat, said method comprising:
- 5 (a) contacting said lymphocyte with PMA and a test agent to form a test cell;
- (b) determining the level of NADPH oxidase activity in said test cell by measuring superoxide;
- (c) determining whether or not said level is less than a control level of NADPH oxidase activity, wherein said control level is the amount of NADPH oxidase activity in a control cell treated with said PMA in the absence of said test agent; and
- 10 (d) identifying said agent as inhibiting NADPH oxidase activity when said level is less than said control level.

- 15 94. A non-DA rat comprising heterologous T-cells from a non-human animal susceptible to arthritis induction, wherein said non-DA rat has arthritis.


95. The rat of claim 94, wherein said rat is an E3 rat.

- 20 96. The rat of claim 94, wherein said non-human animal is a DA rat.

1/25

Figure 1


Clinical scoring of PlA4 congenic rats



Incidence d31: DA (100%), DA.E3+/- (58%) and DA.E3-/- (36%)

Figure 2

Physical map of the Pia4 region





### Figure 3


**cDNA sequence p47phox**

[illegible]

4/25

## Figure 4A

COMP in DA.E3c12 rats



## Figure 4B

AGP in DA.E3c12 rats




Figure 5A

DA




Figure 5B

E3




Figure 5C

DA.E3c12 +/-





Figure 5D


DA.E3c12 -/-



6/25


## Figure 6

Pristane injected rats with NADPH inhibitor DPI injected i.p.



## Figure 7

Accumulated arthritis score




7/25

## Figure 8

### Transfer of pristane/ConA activated T-cells


Clinical scoring day 15 after T-cell transfer



8/25


## Figure 9A

Activation of the oxidative burst by alkanes in vitro (E3 rat cells)



## Figure 9B


Activation of the oxidative burst by alkanes in vitro (HL60 cells)






**Figure 10B**

Arthritis inducing effects of alkanes



**Figure 10C**

Arthritis inducing effects of alkanes




10/25




11/25

Figure 11A



**Figure 11B**

PIA in DA rats treated with  
undecane or undecanol



**Figure 11C**

PIA in DA rats treated with  
undecane or undecanol






Figure 12A

Hexadecane induced arthritis after  
treatment with hexadecene




**Figure 12B**

Hexadecane induced arthritis after treatment with hexadecene




**Figure 12C**

Hexadecane induced arthritis after treatment with hexadecene




14/25

Figure 13




16/25

**Figure 14**  
Tissue distribution of <sup>14</sup>C labelled oils




17/25

**Figure 15**



**Figure 16A**

Treatment of EAE in DA rats with phytol



**Figure 16B**

Treatment of EAE in DA rats with phytol








Figure 17A




**Figure 17B**

Effect of treatment of PIA using phytol  
with different routs of administration




**Figure 17C**

Effect of treatment of PIA using phytol  
with different routs of administration



20/25


Figure 18A



22/25


## Figure 18B

Maximal arthritis score




## Figure 18C

Accumulated arthritis score




23/25

**Figure 19**  
Onset of disease




**Figure 20**

Serum COMP



**Figure 21**


anti collagen antibodies





24/25

## Figure 22

### CIA in rats treated with phytol



25/25

**Figure 23A****Treatment of active PIA with phytol****Figure 23B****Treatment of active PIA with undecane**

## SEQUENCE LISTING

&lt;110&gt; Arexis AB

<120> Autoimmune Conditions and NADPH Oxidase  
Defects

&lt;130&gt; 11145-024W01

&lt;150&gt; US 60/380,904

&lt;151&gt; 2002-05-13

&lt;150&gt; US 60/429,609

&lt;151&gt; 2002-11-27

&lt;160&gt; 8

&lt;170&gt; FastSEQ for Windows Version 4.0

&lt;210&gt; 1

&lt;211&gt; 1349

&lt;212&gt; DNA

&lt;213&gt; Rattus norvegicus

&lt;400&gt; 1

```

gccactgccc agccatgggg gacaccttca ttcgccacat cgcctcctg ggcttcgaga      60
aacgcttcgt cccagccaa cactatgtgt acatgttcct ggttaagtgg caggacctgt      120
cggagaaggt ggtctacaga aaattcacgg agatctacga gttccataaa atgttaaagg      180
agatgttccc cattgaggcc ggtgagatcc acacagaaaa cagagtcac cctcacctcc      240
cagctcccag gtggtatgat gggcagcgtg cagcggagag ccgccaggga acgctcaccg      300
agtacttcaa cagcctcatg ggactgcccc tgaagatctc ccgctgcccc cacctcttga      360
actttctcaa agtgcggccc gatgacctga agctgccccaa tgacagccag gtgaagaagc      420
cagagacata cctgacggcc aaagatggca agaataatgt agctgacatc atgggtccca      480
tcctccttca gacctatcgg gccatcgctg actacgagaa gggttccaaa acagagatga      540
ccgtggcgac gggagatgtg gtggatgtcg tagagaaaag cgagagtggc tgggtggttt      600
gccagatgaa gacaaaacga ggttgggtcc ctgcctccta tttggagccc cttgacagcc      660
ctgatgaggc agaggacccc gatcccaact acgcagggtg accgtatgta accatcaaag      720
cgtacgctgc tgttgaagag gatgaggtgt ccctgtctga ggggtgaagcc atcgaggtca      780
ttcataagct cctagatggc tgggtgggtg tcaggaaaag ggacatcacc ggctacttcc      840
catccatgta tctgcagaag gctggggagg agataaccca ggcccagcga cagattagaa      900
gccgcggggc accacctcgc aggtcgacca tccgcaatgc acagagcatc caccagcgtt      960
ctcggaagcg cctcagccag gacacctatc gccgcaacag cgtccgattc ctgcagcagc     1020
gcagacgccc ggcgcgacct gggccgcaga gccctgactc aaaggacaat ccacgcactc     1080
cgcgcgccaa accacagcct gcggtgcctc cgagacccag ctcggacctc atcctgcacc     1140
gctgcacaga gagcaccaag aggaaactga cgtccgcctg gtgaggggag gctgcactga     1200
aaggcgggtc tatccctacc cttgtatata tttgtatata gcctcaggtc agaggctcct     1260
accctgcttt aatgtttgga atggactcag actctgcagc aaaggacagg actgggtttc     1320
tctccacggg tattgctagg atgagagga

```

&lt;210&gt; 2

&lt;211&gt; 389

&lt;212&gt; PRT

&lt;213&gt; Rattus norvegicus

&lt;400&gt; 2



```

Met Gly Asp Thr Phe Ile Arg His Ile Ala Leu Leu Gly Phe Glu Lys
 1          5          10          15
Arg Phe Val Pro Ser Gln His Tyr Val Tyr Met Phe Leu Val Lys Trp
          20          25          30
Gln Asp Leu Ser Glu Lys Val Val Tyr Arg Lys Phe Thr Glu Ile Tyr
          35          40          45
Glu Phe His Lys Met Leu Lys Glu Met Phe Pro Ile Glu Ala Gly Glu
          50          55          60
Ile His Thr Glu Asn Arg Val Ile Pro His Leu Pro Ala Pro Arg Trp
          65          70          75          80
Tyr Asp Gly Gln Arg Ala Ala Glu Ser Arg Gln Gly Thr Leu Thr Glu
          85          90          95
Tyr Phe Asn Ser Leu Met Gly Leu Pro Met Lys Ile Ser Arg Cys Pro
          100          105          110
His Leu Leu Asn Phe Phe Lys Val Arg Pro Asp Asp Leu Lys Leu Pro
          115          120          125
Asn Asp Ser Gln Val Lys Lys Pro Glu Thr Tyr Leu Thr Ala Lys Asp
          130          135          140
Gly Lys Asn Asn Val Ala Asp Ile Met Gly Pro Ile Ile Leu Gln Thr
          145          150          155          160
Tyr Arg Ala Ile Ala Asp Tyr Glu Lys Gly Ser Lys Thr Glu Met Thr
          165          170          175
Val Ala Thr Gly Asp Val Val Asp Val Val Glu Lys Ser Glu Ser Gly
          180          185          190
Trp Trp Phe Cys Gln Met Lys Thr Lys Arg Gly Trp Val Pro Ala Ser
          195          200          205
Tyr Leu Glu Pro Leu Asp Ser Pro Asp Glu Ala Glu Asp Pro Asp Pro
          210          215          220
Asn Tyr Ala Gly Glu Pro Tyr Val Thr Ile Lys Ala Tyr Ala Ala Val
          225          230          235          240
Glu Glu Asp Glu Val Ser Leu Ser Glu Gly Glu Ala Ile Glu Val Ile
          245          250          255
His Lys Leu Leu Asp Gly Trp Trp Val Val Arg Lys Gly Asp Ile Thr
          260          265          270
Gly Tyr Phe Pro Ser Met Tyr Leu Gln Lys Ala Gly Glu Glu Ile Thr
          275          280          285
Gln Ala Gln Arg Gln Ile Arg Ser Arg Gly Ala Pro Pro Arg Arg Ser
          290          295          300
Thr Ile Arg Asn Ala Gln Ser Ile His Gln Arg Ser Arg Lys Arg Leu
          305          310          315          320
Ser Gln Asp Thr Tyr Arg Arg Asn Ser Val Arg Phe Leu Gln Gln Arg
          325          330          335
Arg Arg Pro Ala Arg Pro Gly Pro Gln Ser Pro Asp Ser Lys Asp Asn
          340          345          350
Pro Ser Thr Pro Arg Ala Lys Pro Gln Pro Ala Val Pro Pro Arg Pro
          355          360          365
Ser Ser Asp Leu Ile Leu His Arg Cys Thr Glu Ser Thr Lys Arg Lys
          370          375          380
Leu Thr Ser Ala Val
          385

```

&lt;210&gt; 3

&lt;211&gt; 1331

&lt;212&gt; DNA

&lt;213&gt; Rattus norvegicus

&lt;400&gt; 3

```

cagccatggg ggacaccttc attcgccaca tcgccctcct gggcttcgag aaacgcttcg      60
tccccagcca acactatgtg tacatgttcc tgggtaagtg gcaggacctg tcggagaagg      120
tgggtctacag aaaattcacc gagatctacg agttccataa aatgttaaag gagatgttcc      180
ccattgaggc cggtgagatc cacacagaaa acagagtcac ccctcacctc ccagctccca      240
ggtaggtatga tgggcagcgt gcagcggaga gccgccaggg aacgctcacc gagtacttca      300
acagcctcat gggactgccc gtgaagatct cccgctgccc acacctcttg aacttcttca      360
aagtgcggcc cgatgacctg aagctgcccc atgacagcca ggtgaagaag ccagagacat      420
acctgacggc caaagatggc aagaataatg tagctgacat cacgggtccc atcatccttc      480
agacctatcg ggccatcgct gactacgaga aggggtccaa aacagagatg accgtggcga      540
cgggagatgt ggtggatgtc gtagagaaaa gcgagagtgg ctggtgggtt tgccagatga      600
agacaaaacg aggttgggtc cctgcatcct atttggagcc ccttgacagc cctgatgagg      660
cagaggaccc cgatcccaac tacgcagggtg aaccgtatgt aaccatcaaa gcgtacgctg      720
ctggtgaaga ggtgaggtg tcctgtctct aggggtgaagc catcgagggtc attcataagc      780
tcctagatgg ctggtgggtg gtcaggaaag gggacatcac cggctacttc ccattcatgt      840
atctgcagaa ggctggggag gagataacc aggccagcg acagattaga agccgcgggg      900
caccacctcg caggtcgacc atccgcaatg cacagagcat ccaccagcgt tctcgaagc      960
gcctcagcca ggacacctat cgccgcaaca gcgtccgatt cctgcagcag cgcagacgcc     1020
cggcgcgacc tgggccgcag agccctgact caaaggacaa tccatcgact ccgcgcgcca     1080
aaccacagcc tgcggtgcct ccgagaccca gctcggacct catcctgcac cgctgcacag     1140
agagcaccaa gcggaaactg acgtccgccg tgtgaggggc ggctgcaactg aaaggcgggtc     1200
ctatccctac ccttgatatat atttgatat agcctcaggt cagaggctcc taccctgctt     1260
taatgtttgg aatggactca gactctgcag caaaggacag gactgggttt ctctccacgg     1320
gtattgctag g                                     1331

```

&lt;210&gt; 4

&lt;211&gt; 389

&lt;212&gt; PRT

&lt;213&gt; Rattus norvegicus

&lt;400&gt; 4

```

Met Gly Asp Thr Phe Ile Arg His Ile Ala Leu Leu Gly Phe Glu Lys
 1           5           10          15
Arg Phe Val Pro Ser Gln His Tyr Val Tyr Met Phe Leu Val Lys Trp
 20          25          30
Gln Asp Leu Ser Glu Lys Val Val Tyr Arg Lys Phe Thr Glu Ile Tyr
 35          40          45
Glu Phe His Lys Met Leu Lys Glu Met Phe Pro Ile Glu Ala Gly Glu
 50          55          60
Ile His Thr Glu Asn Arg Val Ile Pro His Leu Pro Ala Pro Arg Trp
 65          70          75          80
Tyr Asp Gly Gln Arg Ala Ala Glu Ser Arg Gln Gly Thr Leu Thr Glu
 85          90          95
Tyr Phe Asn Ser Leu Met Gly Leu Pro Val Lys Ile Ser Arg Cys Pro
100          105          110
His Leu Leu Asn Phe Phe Lys Val Arg Pro Asp Asp Leu Lys Leu Pro
115          120          125
Asn Asp Ser Gln Val Lys Lys Pro Glu Thr Tyr Leu Thr Ala Lys Asp
130          135          140
Gly Lys Asn Asn Val Ala Asp Ile Thr Gly Pro Ile Ile Leu Gln Thr
145          150          155          160
Tyr Arg Ala Ile Ala Asp Tyr Glu Lys Gly Ser Lys Thr Glu Met Thr
165          170          175
Val Ala Thr Gly Asp Val Val Asp Val Val Glu Lys Ser Glu Ser Gly
180          185          190
Trp Trp Phe Cys Gln Met Lys Thr Lys Arg Gly Trp Val Pro Ala Ser

```

195	200	205
Tyr Leu Glu Pro Leu Asp Ser Pro Asp Glu Ala Glu Asp Pro Asp Pro		
210	215	220
Asn Tyr Ala Gly Glu Pro Tyr Val Thr Ile Lys Ala Tyr Ala Ala Val		
225	230	235
Glu Glu Asp Glu Val Ser Leu Ser Glu Gly Glu Ala Ile Glu Val Ile		
245	250	255
His Lys Leu Leu Asp Gly Trp Trp Val Val Arg Lys Gly Asp Ile Thr		
260	265	270
Gly Tyr Phe Pro Ser Met Tyr Leu Gln Lys Ala Gly Glu Glu Ile Thr		
275	280	285
Gln Ala Gln Arg Gln Ile Arg Ser Arg Gly Ala Pro Pro Arg Arg Ser		
290	295	300
Thr Ile Arg Asn Ala Gln Ser Ile His Gln Arg Ser Arg Lys Arg Leu		
305	310	315
Ser Gln Asp Thr Tyr Arg Arg Asn Ser Val Arg Phe Leu Gln Gln Arg		
325	330	335
Arg Arg Pro Ala Arg Pro Gly Pro Gln Ser Pro Asp Ser Lys Asp Asn		
340	345	350
Pro Ser Thr Pro Arg Ala Lys Pro Gln Pro Ala Val Pro Pro Arg Pro		
355	360	365
Ser Ser Asp Leu Ile Leu His Arg Cys Thr Glu Ser Thr Lys Arg Lys		
370	375	380
Leu Thr Ser Ala Val		
385		

&lt;210&gt; 5

&lt;211&gt; 1349

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 5

gagcactgga	ggccacccag	tcattggggga	caccttcac	cgtcacatcg	ccctgctggg	60
ctttgagaag	cgcttcgtac	ccagccagca	ctatgtgtac	atgttccttg	tgaaatggca	120
ggacctgtcg	gagaaggtgg	tctaccggcg	cttcaccgag	atctacgagt	tccataaaac	180
cttaaaagaa	atgttcctta	ttgaggcagg	ggcgatcaat	ccagagaaca	ggatcatccc	240
ccacctccca	gctcccaagt	ggtttgacgg	gcagcggggc	gccgagaacc	gccagggcac	300
acttaccgag	tactgcagca	cgctcatgag	cctgcccacc	aagatctccc	gctgtcccca	360
cctcctcgac	ttcttcaagg	tgcgccctga	tgacctcaag	ctccccacgg	acaaccagac	420
aaaaaagcca	gagacatact	tgatgcccaa	agatggcaag	agtaccgcga	cagacatcac	480
cggccccatc	atcctgcaga	cgtaccgcgc	cattgccgac	tacgagaaga	cctcgggctc	540
cgagatggct	ctgtccacgg	gggacgtggt	ggaggtcgtg	gagaagagcg	agagcggttg	600
gtggttctgt	cagatgaaag	caaagcgagg	ctggatccca	gcattccttc	tcgagccctt	660
ggacagtctt	gacgagacgg	aagaccctga	gccaactat	gcaggtgagc	catacgtcgc	720
catcaaggcc	tacactgctg	tggaggggga	cgaggtgtcc	ctgctcgagg	gtgaagctgt	780
tgaggtcatt	cacaagctcc	tggacggctg	gtgggtcatc	aggaaagacg	acgtcacagg	840
ctactttccg	tccatgtacc	tgcaaaagtc	ggggcaagac	gtgtcccagg	cccaacgcca	900
gatcaagcgg	ggggcgccgc	cccgcaggtc	gtccatccgc	aacgcgcaca	gcattccatca	960
gcggtcgccg	aagcgcctca	gccaggacgc	ctatcgccgc	aacagcgtcc	gttttctgca	1020
gcagcgacgc	cgccaggcgc	ggccgggacc	gcagagcccc	gggagccccgc	tcgaggagga	1080
gcggcagacg	cagcgctcta	aaccgcagcc	ggcggtgccc	ccgcggccga	gcgcgcacct	1140
catcctgaac	cgctgcagcg	agagcaccaa	gcggaagctg	gcgtctgccg	tctgaggtcg	1200
gagcgcagtc	cccagctagc	gtctcggccc	ttgccgcccc	gtgcctgtac	atacgtgttc	1260
tatagagcct	ggcgtctgga	cgccgagggc	agccccgacc	cctgtccagc	gcggctcccc	1320
ccaccctcaa	taaagtgtgc	ttggagtgg				1349

<210> 6  
 <211> 390  
 <212> PRT  
 <213> Homo sapiens

<400> 6  
 Met Gly Asp Thr Phe Ile Arg His Ile Ala Leu Leu Gly Phe Glu Lys  
 1 5 10 15  
 Arg Phe Val Pro Ser Gln His Tyr Val Tyr Met Phe Leu Val Lys Trp  
 20 25 30  
 Gln Asp Leu Ser Glu Lys Val Val Tyr Arg Arg Phe Thr Glu Ile Tyr  
 35 40 45  
 Glu Phe His Lys Thr Leu Lys Glu Met Phe Pro Ile Glu Ala Gly Ala  
 50 55 60  
 Ile Asn Pro Glu Asn Arg Ile Ile Pro His Leu Pro Ala Pro Lys Trp  
 65 70 75 80  
 Phe Asp Gly Gln Arg Ala Ala Glu Asn Arg Gln Gly Thr Leu Thr Glu  
 85 90 95  
 Tyr Cys Ser Thr Leu Met Ser Leu Pro Thr Lys Ile Ser Arg Cys Pro  
 100 105 110  
 His Leu Leu Asp Phe Phe Lys Val Arg Pro Asp Asp Leu Lys Leu Pro  
 115 120 125  
 Thr Asp Asn Gln Thr Lys Lys Pro Glu Thr Tyr Leu Met Pro Lys Asp  
 130 135 140  
 Gly Lys Ser Thr Ala Thr Asp Ile Thr Gly Pro Ile Ile Leu Gln Thr  
 145 150 155 160  
 Tyr Arg Ala Ile Ala Asp Tyr Glu Lys Thr Ser Gly Ser Glu Met Ala  
 165 170 175  
 Leu Ser Thr Gly Asp Val Val Glu Val Val Glu Lys Ser Glu Ser Gly  
 180 185 190  
 Trp Trp Phe Cys Gln Met Lys Ala Lys Arg Gly Trp Ile Pro Ala Ser  
 195 200 205  
 Phe Leu Glu Pro Leu Asp Ser Pro Asp Glu Thr Glu Asp Pro Glu Pro  
 210 215 220  
 Asn Tyr Ala Gly Glu Pro Tyr Val Ala Ile Lys Ala Tyr Thr Ala Val  
 225 230 235 240  
 Glu Gly Asp Glu Val Ser Leu Leu Glu Gly Glu Ala Val Glu Val Ile  
 245 250 255  
 His Lys Leu Leu Asp Gly Trp Trp Val Ile Arg Lys Asp Asp Val Thr  
 260 265 270  
 Gly Tyr Phe Pro Ser Met Tyr Leu Gln Lys Ser Gly Gln Asp Val Ser  
 275 280 285  
 Gln Ala Gln Arg Gln Ile Lys Arg Gly Ala Pro Pro Arg Arg Ser Ser  
 290 295 300  
 Ile Arg Asn Ala His Ser Ile His Gln Arg Ser Arg Lys Arg Leu Ser  
 305 310 315 320  
 Gln Asp Ala Tyr Arg Arg Asn Ser Val Arg Phe Leu Gln Gln Arg Arg  
 325 330 335  
 Arg Gln Ala Arg Pro Gly Pro Gln Ser Pro Gly Ser Pro Leu Glu Glu  
 340 345 350  
 Glu Arg Gln Thr Gln Arg Ser Lys Pro Gln Pro Ala Val Pro Pro Arg  
 355 360 365  
 Pro Ser Ala Asp Leu Ile Leu Asn Arg Cys Ser Glu Ser Thr Lys Arg  
 370 375 380  
 Lys Leu Ala Ser Ala Val  
 385 390

```
<210> 7
<211> 390
<212> PRT
<213> Homo sapiens
```

<400> 7															
Met	Gly	Asp	Thr	Phe	Ile	Arg	His	Ile	Ala	Leu	Leu	Gly	Phe	Glu	Lys
1				5					10					15	
Arg	Phe	Val	Pro	Ser	Gln	His	Tyr	Val	Tyr	Met	Phe	Leu	Val	Lys	Trp
			20					25					30		
Gln	Asp	Leu	Ser	Glu	Lys	Val	Val	Tyr	Arg	Arg	Phe	Thr	Glu	Ile	Tyr
		35					40					45			
Glu	Phe	His	Lys	Thr	Leu	Lys	Glu	Met	Phe	Pro	Ile	Glu	Ala	Gly	Ala
		50				55					60				
Ile	Asn	Pro	Glu	Asn	Arg	Ile	Ile	Pro	His	Leu	Pro	Ala	Pro	Lys	Trp
65				70						75				80	
Phe	Asp	Gly	Gln	Arg	Ala	Ala	Glu	Asn	Arg	Gln	Gly	Thr	Leu	Thr	Glu
				85					90					95	
Tyr	Cys	Ser	Thr	Leu	Met	Ser	Leu	Pro	Thr	Lys	Ile	Ser	Arg	Cys	Pro
			100					105					110		
His	Leu	Leu	Asp	Phe	Phe	Lys	Val	Arg	Pro	Asp	Asp	Leu	Lys	Leu	Pro
		115					120					125			
Thr	Asp	Asn	Gln	Thr	Lys	Lys	Pro	Glu	Thr	Tyr	Leu	Met	Pro	Lys	Asp
		130				135					140				
Gly	Lys	Ser	Thr	Ala	Thr	Asp	Ile	Thr	Gly	Pro	Ile	Ile	Leu	Gln	Ser
145				150						155				160	
Tyr	Arg	Ala	Ile	Ala	Asn	Tyr	Glu	Lys	Thr	Ser	Gly	Ser	Glu	Met	Ala
				165					170					175	
Leu	Ser	Thr	Gly	Asp	Val	Val	Glu	Val	Val	Glu	Lys	Ser	Glu	Ser	Gly
			180				185						190		
Trp	Trp	Phe	Cys	Gln	Met	Lys	Ala	Lys	Arg	Gly	Trp	Ile	Pro	Ala	Ser
		195				200						205			
Phe	Leu	Glu	Pro	Leu	Asp	Ser	Pro	Asp	Glu	Thr	Glu	Asp	Pro	Glu	Pro
		210				215					220				
Asn	Tyr	Ala	Gly	Glu	Pro	Tyr	Val	Ala	Ile	Lys	Ala	Tyr	Thr	Ala	Val
225				230						235				240	
Glu	Gly	Asp	Glu	Val	Ser	Leu	Leu	Glu	Gly	Glu	Ala	Val	Glu	Val	Ile
			245						250					255	
His	Lys	Leu	Leu	Asp	Gly	Trp	Trp	Val	Ile	Arg	Lys	Asp	Asp	Val	Thr
			260					265					270		
Gly	Tyr	Phe	Pro	Ser	Met	Tyr	Leu	Gln	Lys	Ser	Gly	Gln	Asp	Val	Ser
		275				280						285			
Gln	Ala	Gln	Arg	Gln	Ile	Lys	Arg	Gly	Ala	Pro	Pro	Arg	Arg	Ser	Ser
		290				295					300				
Ile	Arg	Asn	Val	His	Ser	Ile	His	Gln	Arg	Ser	Arg	Lys	Arg	Leu	Ser
305				310						315				320	
Gln	Asp	Ala	Tyr	Arg	Arg	Asn	Ser	Val	Arg	Phe	Leu	Gln	Gln	Arg	Arg
				325					330					335	
Arg	Gln	Ala	Arg	Pro	Gly										

385

390

&lt;210&gt; 8

&lt;211&gt; 17302

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 8

gagaatcgct	tgaacctgga	aggcagaggt	tgcagtgcgc	cgagattgtg	ccactgcact	60
ccagcttggg	caacaagagc	gaaacttcgc	ttcaaacaaa	taaattaacg	cccagcatgt	120
cttggctttc	atctgccaga	cctcaaccct	cacccccagg	agatcaggte	cggaccatga	180
gctgaccttg	gactcaggca	aggggtgagtt	gggtgcagccc	tggcctgctg	ggaggcacag	240
gctgcagcag	gctgcctggg	gctgaggccc	gccactcatg	aactcatgac	cttgaatgag	300
ctccaaaagc	tctgggcctc	ccaggctcta	gggggagtg	gagagagagg	cctcagcctg	360
tccttgggca	tgctgcccc	tcctcacctc	tttgtcccaa	atcccccttc	tggaagagct	420
gacagtctta	atatcactct	ggagaaaact	gagtcagccc	taaggaaaca	ttcaatgaac	480
catttgctta	cttgaggatt	ggaactcaag	tctcactcaa	agtctgtgcc	attttcgtcc	540
cagctgtcac	tggccctcat	ccacacacac	ccaaggatga	gcactcaacg	cttgcattga	600
cactcccatg	cccgcgttca	ttcactcatt	cattcattca	ttcactcatt	cattgactca	660
ttcattcatt	cactcactca	ttcattcact	cagtgaatgt	tgcagtcacg	atccaaatat	720
ttatggcctc	tgtgtgccag	gcactagatg	gaggggctgg	ggctagagcc	cctgataacc	780
cggctatgcc	ctagctttcc	tgggacacac	attgtggtaa	ggggagacta	aaaaaattaa	840
gtcaggccag	gcacggtggc	tcatgcctga	atcccagcac	tttgggaggc	cgaggcgagt	900
gaattacctg	aggctcaggag	ttcaagacca	gcctggccaa	catggagaaa	cccagctctc	960
aattaaaaaa	aaaaaaatta	cccagggtgtg	gtggcacatg	cctgtaatcc	cagggtactca	1020
ggagactaac	gcaagagaat	tgcttgaacc	caggaggcag	aggttgccgt	gagccgagat	1080
cgcgccattg	cactccagcc	tgggaaacaa	gagcgagact	ccatctcaaa	aaaaaaaaaag	1140
tgggaggcag	aggcaggagg	atcactagag	gccagtagtt	tgagaccatc	ctgggcaaca	1200
tagcaggacc	ctgtctgtac	aaaaaaatta	aaaaaaattt	aaccgggcat	ggtggcacac	1260
accctagctc	ccagctactc	cagaggctga	gggcccgctg	tcgctggagc	ccaggagtgt	1320
gaggctgcag	tgaactgtga	tcccaccact	gcgcttaagc	ctggataaca	aggcaagacc	1380
ctgtctcaaa	taacaatagc	aataataata	aagaaaaatt	aaatgcaatt	tgcatgtcat	1440
cagtataaag	tgctctgcag	aaaaaggagg	caggaaagag	ctgagaaagg	tatgaggttt	1500
gctatgcaat	gtgaagtatt	caaggaaagg	ttctcggaa	aggtgacatt	tgagcagaga	1560
aatggaggag	agttatggag	ggaagatggg	gaatgggggg	aacatgggtc	agaccaggaa	1620
tatggtcaag	gggggaaaga	tggtcaaggg	gacgcagcaa	atgcaaaggc	cctgaggcag	1680
gagcagcttg	attcaccccc	aaaaccctgt	gggcccgctg	aggcgacggg	aaggacaagt	1740
gtaaacccctt	ttccttgtcc	ctgcagggtg	gtgtgaacat	gagtcctgcc	atgtttacac	1800
cctgcaagcc	tgaagagtcc	ccagaaactg	aaagaagaag	caaagccctt	tctgtaccct	1860
ccctgcccc	tgtcccagcc	gcgacaaaag	cgacttcctc	tttccagtgc	atttaaggcg	1920
cagcctggaa	gtgccaggga	gcactggagg	ccaccagctc	atgggggaca	ccttcattccg	1980
tcacatcgcc	ctgctgggct	ttgagaagcg	cttcgtaccc	agccagcact	atgtgagtag	2040
ctggtggagg	gcacccccgt	ggggggaata	cgggagggac	agcacggcca	cccttgagct	2100
cccaggggcca	accagctcca	gtgaggacta	acggggcagg	gtcttgggca	cctggtccct	2160
ggtctttgag	cctggatcta	cccctctgat	ccctgggaag	acagttccct	tggaccgcc	2220
ctgggcccc	ggcctttact	gtccccgcct	gtgtccccag	ccaggccctc	agccttagcc	2280
aggagtccct	tttctgtctc	cctgccatgg	ccaggcagcc	cagcgctctc	tcaggtccga	2340
ggcccaactc	tccagggaagc	cttccttgac	tagcccagct	atcagagagt	ggccctccca	2400
agagggaggc	ctggaacta	aagctctctc	tctccccagc	tgctgtagtg	gtcagttaga	2460
gtcttatcct	ctccagtagg	gtgacacat	gacaggggac	aatagagtcc	tcccatctgt	2520
ccccaaaggag	gctggacaaa	tgctgtctca	gacacacaag	tccactgggt	cccctaacc	2580
cataggaagg	ccagggagga	actacattta	ggaaattgaa	gcttgtatgg	aacatttagt	2640
cctatgtgcc	aagacctttc	tcttttttgt	tatttttttg	tgttttgaga	cagagtcttg	2700
atctgttgcc	caggccagag	tgagtgagca	cgatctcagc	tcactgaaac	ctccgccttc	2760
caggttcaac	tggttctcct	gcctcagcct	ccagagtagt	tgggattaca	ggtgccacc	2820
accacgcctg	gctaattttt	gtatttttag	tagagacagg	gtttcaccat	gttgccaga	2880

ctgggtctcaa	actcctgacc	tcaagtgatc	caccacacctg	ggcctcccaa	agtgtctggga	2940
ttacaggcat	gagccaccgt	gcctggcctg	tttttttgaa	atgaggctctg	gagtgcagtg	3000
gtgcgatcat	agttcactgc	agcctcaagc	tcccaggccc	aagtgatccg	cctgcctcaa	3060
ccccttgagt	agctggggct	acaggcgcac	accaccatgc	ctggctagtt	tttaaaattt	3120
ttgtggagat	gaggtttcac	tatgtttgcc	aggctaactc	tgaactcctc	ggcttaagca	3180
accctctggg	ctcagcctcc	cacagtgcct	ggattacaag	cgtgagctac	cgtgcctagt	3240
cactttttctc	ctttttcttg	taactttcag	ttttgaaatt	tcaaatttac	agaaaaggcta	3300
ctgggtgtca	aaacgggtacc	agtcactcca	atagtctttc	actcaccttc	atccacacct	3360
ctctttctgg	ggatattttc	tgaattattt	gagagtgcgt	tgaagacgtg	tttctttacc	3420
tctaaatact	acttggtggg	catttcttaa	aatcaaggca	ttctcttaca	taatcacaac	3480
acacgtgtca	aaatcaggaa	attaacatgg	acaaaacacc	attatccacc	cacagacttt	3540
actgagggtt	cccgcattat	cctgcttgct	ctctgcagtg	aaaacttttt	tcagggtctag	3600
gatccagtc	aggatcaatg	tcatagcctt	taaccttctt	taatctggat	cagtcttttt	3660
tctttttctt	tctttttttt	tggacacgga	atctcactct	gtcgccagac	tggagtgcag	3720
tgggtgcaatc	tcggctcatt	gcaacctctg	cctctgggtt	tcaagagatt	ctcctgcctc	3780
agcctcctga	gttagctggg	aatacagggtg	cgcgccacca	tgcccagctc	gcattttttg	3840
gtagagacag	ggttttgcc	tattgattct	ggatcagctc	tttttttttt	ttatgaaatg	3900
gattcttact	ctgtcaccca	ggctggattg	caatggcaca	atctccactc	actgcactct	3960
ccgcctccca	ggttcaagca	attctcgtgc	ctcagcctcc	cgagttagctg	ggattacagg	4020
catgcgccac	catgcccggc	tactttttgt	atttttagta	gagacagggt	ttcacatgt	4080
tagccaggct	gatctogaac	tcctgacgtc	aggatgctct	ccgcctcga	cctcccaaag	4140
tgctgggatt	acaggcgtga	gccacgcgtc	cagcgggattc	tggatcggtc	ttaatcagtc	4200
tttgtctttt	gcaactttga	tgttttgcat	agagcagacc	agttaccttg	tagaatgtcc	4260
cttagttttg	gtttatcttc	attagattca	gtttgtgtat	ccagggcagt	ggatcttaga	4320
tgcaattctg	tcttcttttt	aatttttttg	agagggagtc	tcgctctgtc	accagggctg	4380
gagtgcagtg	gcacaacctc	agctcactgc	agcctccgcc	tcccgggttc	aagcaattct	4440
cctgtcccag	cctcccaagt	agctgggac	acaggtgccc	atcaccacta	ccgggttaatt	4500
tttgtgtttt	tagtagagac	agggtttcac	catattggct	aggctggctc	tgaacgcctg	4560
acctcagggt	atccacctgc	cttggcctcc	cattagtgctg	ggattacaga	cgggagccaa	4620
catgcccagc	cttctctgcc	ctcccgctcc	ctccctcttc	ctcctgtccc	ctcccttccc	4680
ctccctcttc	ctcctgtccc	ctcccttccc	ctccctcttc	cacccaagct	ggagtgcagt	4740
ggtgcaatca	tagctcacta	aagccttgac	ctccaagtct	caagcaattc	tcctgcctca	4800
cctggggcca	cagggtgtgcg	gcaccacacc	cggacaattt	ttgtgttttt	agtagatatg	4860
ggggtctcgc	tatgttgccc	aggctggctc	caaactcttg	gactcaagcg	atcttcccac	4920
ctcggctact	aaaagtgtcg	ggattccagg	tgtgagccac	cgtgcccagc	ctaggtccta	4980
cttttatctc	caatttacag	atgagtcct	ttgagagaag	ctgacctctc	tgcctgggtt	5040
ctcaaggctg	gggcgtggca	gcacttgggt	ccacgtttgt	gccctttctg	caatccagga	5100
caaccgcaaa	gatggtcctc	accccaatcc	tctgggcttc	ctccagtggg	tagtgggac	5160
ctgggtgcac	acagcaaagc	ctctttggag	gctaaatggg	gtcccccgac	tctggctttc	5220
cccagggtgt	acatgttctt	ggtgaaatgg	caggacctgt	cggagaagggt	ggtctaccgg	5280
cgcttcaccg	agatctacga	gttccatgtg	agtgtgggga	cggaggagggt	acagggaccc	5340
accgttccag	ctccaccctt	tgggaaggac	cttagcccag	gtgatgggga	aactgcagaa	5400
cccagaatcc	ccttccagac	cacagttaaa	ggggatttat	ttattttatat	aaatttttgt	5460
gacagggtct	tgtctgttca	ccactctgaa	cacctcatgt	tctctgatta	caggcatgag	5520
ccccacgct	cggcctttta	ggtgggtttt	agaggatttt	aggtttgcag	tgagggggct	5580
caatcatagc	tactgcagc	ctcgacctct	ggggctcaag	cgatcctcct	gcctcagcct	5640
cctgagtagc	tgggactata	ggtgcgcctc	accatgtgtg	gctaattttt	gtatttttta	5700
taaagatggg	gatctcacta	tgttgcccag	gctggtcttg	aactccagac	ctcaagtgat	5760
cctcctgcct	tggcctccca	aagctagggg	ggcattaaaa	gaaaaaacat	ttttccccct	5820
gaaacattta	agtagtctta	ctgaaaaaaa	taaaaacacag	aaacaccaga	ttctcatttt	5880
aaagtaaaac	agacaggatc	tcccagaacc	ttcctagaat	ggaaccattc	ttgtcgcttt	5940
tgaaaaaaaa	agccaagtgc	tagatcccaa	ataaatgcac	ctgctgggtg	acattctcct	6000
tgtgggtctc	gtccctatgt	tagttatttt	cctaaatttt	acatttgtac	ctttttaaga	6060
atgagttatc	agttttttta	tatttgcctt	tcttttgaga	tgggggtctg	ctctgtcacc	6120
caggctgggg	tgcagtgggt	caatcacggc	tactgcagc	ctcaacctcc	agggtggaag	6180
cgattctccc	atctcagcct	cccattgtga	gatcacagggt	gtgcaccacc	acacctggct	6240

ccttttctctg	atttggtttt	tgtagagatg	ggatttcgct	atgttgccca	ggctgggtctc	6300
taactcctgg	actcaagtga	tcctcccgcc	tcagcttccc	aaattgctag	gattacaggt	6360
ttgagccct	gcacctggtc	aacctgagtt	ttaagaggat	ccctttggcg	actggattga	6420
ggacagacaa	gagtggaagg	gggacacaag	gaggccattt	tcgttatcca	ggcctggtag	6480
tggctagggc	caggaggggtg	gggttgggtg	gaagcagtca	gatcccaaag	agatttgggg	6540
attggaagca	aaaggatttg	ctggtgactt	gcacatggga	gggagagagg	tcagtgcctc	6600
tgctaataca	ggaatccaga	ttgccaccga	aatttctagg	cccgagatat	ttaggtagtg	6660
tctcactctg	tcaccagga	tggagtgcag	tggcgcatc	tcggctcact	gtaacctccg	6720
cctcccagggt	ttaagcgatt	ctcccacctc	agcctcctga	gtagctggga	ttacaggcat	6780
gtgccaccac	tcccggttaa	tttttgtatt	tttagtagag	acgggggttc	accacgttgg	6840
ccaggtcggg	cttgaactcc	tgacctcaag	tgatccaccc	acgacagcct	cccaaagtgc	6900
tgggattaca	ggcgtgagcc	accatgctcg	gccttttagg	tggttttgag	aggtatttag	6960
gtcacttcca	atctcgtgct	tttccaagtg	ttgtaaacta	caaatattec	ttcacgtctt	7020
cttgtctttt	taatgtttag	aaaaccttaa	aagaaatgtt	ccctatttag	gcaggggcga	7080
tcaatccaga	gaacaggatc	atccccacc	ccactgtga	gcacggggct	gagccgctg	7140
tcacgggggtc	attggcgggg	gctcacctgc	cctcccagcc	cctctcgggc	ttgacctcat	7200
gttctctggt	gccagctccc	aagtggtttg	acgggcagcg	ggccgcccag	aaccgcccagg	7260
gcacacttac	cgagtactgc	agcacgtca	tgagcctgcc	caccaagatc	tcccgtgtc	7320
cccacctcct	cgacttcttc	aagggtgcgc	ctgatgacct	caagctcccc	acggacaacc	7380
agtgaagtga	cttttcaccc	tgccaggtgg	gagagggaa	gaggggtggg	actttctgtg	7440
ttttgcagat	gaggaaacca	aggctcagag	agggaaaagg	accttcccag	agccacacag	7500
ccagaaagag	gaggcaaat	ccacctccgg	ccctgtgac	cccgccaagc	ctccacctta	7560
atctttcaca	cctagggcac	tgggggaagc	actcggggct	ggaggttcaa	agtcctgggt	7620
cctcatcctg	acattatggc	cacctggcta	tgggacctgg	agccagtcac	cactgctctc	7680
tgaatgcagg	ttctccattt	ctataatggg	cagtgaggat	cagatgaagc	attgggtgtc	7740
ttgcggagcc	cccagaagg	atgtgggggt	gatgcctctg	ctaagtgtctg	agcatgtctg	7800
gggtctcctg	taccaggac	cctgtgtgga	aggcacctga	gaggctgagg	gagctccagg	7860
caggctgggg	aagtcccctt	ctccactcct	ctctggtcac	tgaagctcga	agtggggagc	7920
atgaggacag	gacgttacct	cttgtcaagg	cctccaggct	gccaaagacag	agacaagcag	7980
cattgtcccg	gccagcactt	attgacgctt	gaaggtgtcc	cctggcccaa	ggaaggcgag	8040
ttatcatcag	cccgggaggg	gggggaagga	tggactctgc	agtgggggtcc	gctcctcatt	8100
gcctgctctc	tcagggtctc	agaaggagga	agaggccggg	cacagtggct	cacacctata	8160
atcccagcac	tttggaagg	cgaggtgggc	agatcacctg	aagttgggag	tttgagacca	8220
gcctggccaa	catggtgaaa	ccccatctct	acaaaaata	taaaaattta	gtcaggcatg	8280
tggtgtgctg	cttgtaatcc	cagctacttg	ggaggccgag	gcaggagaat	cgcttgaacc	8340
cgggaggcag	aggtttcagt	gagctgagac	tgcccgactg	cactccagcc	tgggtgacag	8400
agcgagactc	tgtctaagga	aaagaaaaga	aaagaagaaa	gaagatggcc	tgggagcccc	8460
caagagcatt	ttccaggctt	agggcatcct	ttgggtctgc	agaaggctat	gcagtgtcct	8520
cctcatgtcc	ctcccttggg	ctgcccgagc	agatccgccc	gccccatca	cttctggaag	8580
cccttctcca	gccagtccag	ttgctgtctt	ctctcccgag	tgcccccttc	ctttcccggg	8640
tcctctctct	tcttgggagt	tcttctgcag	gtctaaccag	tgctctctct	tcctccatgg	8700
gaagtccaga	gggtctcacc	cagactgggt	ctctcctcag	gacaaaaaag	ccagagacat	8760
acttgatgcc	caaagatggc	aagagtaccg	cgacaggtga	gaggacgggg	ggcagccggc	8820
ggggggggac	accctgagga	gaccagagt	gttcaggga	tggagcaggg	gctgggagca	8880
ggctgggagg	gctcacagct	accctgctga	agaattgggt	ctttgggccc	gggtgcggtt	8940
ctcatgcctg	taatcccagc	agtttgggag	gccgaggcag	gtggatcact	tgaggtcagg	9000
agtttgagac	cagcctggcc	aacatggaga	aacctgtct	ctactaaaaa	tccaaattag	9060
ccaggcgtgg	tgacaggtgc	ctgtagtccc	agccacttgg	gaggctgagg	caggagaatt	9120
gcttgaaccc	ggaagacgga	gtttgcagtg	agccgagatc	gtgccactgc	actccagcct	9180
gggcagcaga	gccagactcc	atctcaaaaa	aaaaaaaaaa	aaaaaagaag	aattgggtct	9240
ttggaagggtc	cctggagact	gaaaggagcc	ctttgcagg	ggcagtgacg	agaccagcgc	9300
agacccttgc	tactggcagc	cgggggagtg	tttgcggctg	aatgaatgaa	cagggttttg	9360
agggcagtg	ggccttcaga	ggcgatgcag	gcctgtggca	gtttctaata	cttattgcac	9420
agtcactgct	aataacaata	ataataataa	tacctaacat	taatggagtg	cttactctgt	9480
gccagccact	attttgtttt	tgttgttttc	agtgcagggt	tctcgctctg	ttgccagggc	9540
tagagtgaag	tgggtgatc	atagctcact	acagcctcga	cctcctgggc	tgaagcgatc	9600



ctccacctc	agcctcccaa	gtagctggga	ttacaggtgt	gtgccaccat	gtccagctaa	9660
tttttaattt	tctggtagag	atggggtctc	actacattgc	ccaagctggt	cttaagctct	9720
tggcctcaag	caaccctect	gcctcagcct	cccaaagtgc	tgagattata	gacatgagcc	9780
actgtgcccg	gctttttctt	cttcttataa	ggacacgagg	cctgttgggt	tagggcccac	9840
tctactgacc	tcatttttaat	ttaattacct	cttgaacgt	acttaagagt	acctttctct	9900
taatacaccc	acactgtaag	gtactgggtg	gttaggactt	caacatatga	attttgagaa	9960
ggcggatgtc	agccattact	aaacagcatc	agcacctcca	cggttggatg	aagggtcgtg	10020
cagaaatgca	cactcaggtc	ccacagtggg	cctactgaac	aggataggca	ttttagcaaa	10080
atcccaggta	ttggggtgca	ccttaaagtt	aggaaaaggt	caggcactgt	ggctcatgcc	10140
tgtaatccca	gcactttggg	aggccgaggc	ggttgaatca	cctgagggtc	ggagtctgag	10200
accagcctga	ccaatatcgt	gaaactccat	ctctactaaa	aatacaaaaa	ttagccaggt	10260
gtgggtggcg	gtgcttgtag	tcccagctac	ttgggaggct	gaggcaggtg	aattacttga	10320
acctgggagg	tggaggttgc	aatgagccaa	gattgcacca	ctgcactcca	gtgacagagc	10380
gagactccat	ctcaaaaaaa	aaaaaaaaaa	agttgggaaa	aggccaggtg	cagtggctcc	10440
acgcctgtaa	tcccaacct	ttaagaggct	gagggtggag	aatcctttga	gcccaggagt	10500
tcgagaccag	cctgggcatt	gtcccaagac	cttgtcttta	ccagaaatta	gccgggtgtg	10560
gtggcatacg	tctatggtcc	cagctattcg	ggaggctgag	gcaggggagat	tgcttgagcc	10620
taggagtcca	gggctgtagt	gagctgtgat	cacgtcactg	tactctagcc	tgggcaacag	10680
agcaagactc	tgtctcccaa	aaagaaaata	aagttgggaa	aggctcacta	acttcatcag	10740
atgagaacaa	ggacatgttt	gaagtgtgag	gccgaagcct	ggagaacgct	atgcccagag	10800
gaaatgcagg	gcagcagaga	ctcaagatgc	cagcgctctg	tctggaggcc	cagatgggccc	10860
ctgaagtgcc	gctcaccct	gccctccctc	ttgccccaga	catcaccggc	cccatcatcc	10920
tgcagagcta	ccgcgccatt	gccaactacg	agaagacctc	gggctccgag	atggctctgt	10980
ccacggggga	cgtggtggag	gtcgtagaga	agagcgagag	cggtcagacc	tcccacctta	11040
cggggctcct	tcccctgggt	ctcaggaacc	cacagccaca	aagccccctg	ccaagctcag	11100
gcagcctggc	ccctgggagg	actccggctc	tgttaggggc	cctaaatgtc	ctccccacac	11160
tgtgggtcgc	cttctctctt	agtgtgcacc	ctgtggtggc	tgtgggcatc	tgtgcatggc	11220
aggccggggc	ggggcatgtc	tgcgtgttct	gtctggatgg	gtatgggacc	gtctgttcat	11280
tatgaagtgg	gctcagagct	gtgattctgt	gtgcttgggt	gcatgcatgc	atgtgacctc	11340
attgtccagt	gtggtgaagg	tgacatttcc	aaatctgagc	attggacatc	agtgtgtctg	11400
tgtccctgtg	tectcaccat	ccctgatggc	tgcagggagc	cgctgggccc	tgcccctcag	11460
tcacattccc	gcacctcttg	cacaggttgg	tggttctgtc	agatgaaagc	aaagcgaggc	11520
tggatcccag	catccttcc	cgagcccctg	gacagtccct	acgagacgga	agaccctgag	11580
cccaactatg	caggtgcccc	ctgccctccg	aggctgtagg	ggtgtggggag	aaaggggag	11640
gcagggtcca	gggatattga	gtgactgctt	tggagtctgg	gctggttgtc	gacttggcag	11700
aaaagtccag	gctcaagatc	catcgactct	ggcttggggg	ccctggcagg	ttgtgagccc	11760
cttgggtctg	acagggaaca	ggaggaggag	cagacgactg	gggagagtgg	gaggccagtg	11820
gtgtctgtgg	atatgtggcc	aggttcagtg	ggaagctgaa	ggatgagcag	accttaggct	11880
caggaaaggag	ggctgcctgg	aagtgggggc	atcatcactg	accagaaagg	gaaaactggc	11940
agtgccaggg	ctggatgggg	cctgcattga	gcttgaaaaa	aactataata	gaattggtta	12000
ccatttcatt	ttattattta	tttattttatt	ttactttttt	gagatagagt	ctcactccct	12060
tgctaagggt	gagtgcgggt	gtgctatctc	agctcactgc	aacctctgcc	tcccaggatc	12120
aagtgattct	ccagcctcag	cctccccagg	tagctgggat	tacaagcatg	caccaccatg	12180
cctggataat	ttttgtattt	ttagttagaga	cggggtttca	ccaggttggc	cagactgggtc	12240
tcgaacttct	gacctcaggt	gatctgcctg	cctcggcctc	ccaaagtgtc	ggaattacag	12300
atgtgagcca	ctgtccctgg	cctggttacc	cacattttta	aatggagtga	tttcaccctt	12360
ttatgtggat	ttacagcttg	tttttttttt	ttttgagaca	aagtctgggt	ctgtcaccca	12420
ggctggagtg	cagtaatgca	atctcagctc	actgcaacct	tagcctcctg	ggttcaagca	12480
attctcctgc	ctcagccacc	tgagtactgc	ggattacagg	catgcaccac	cacgcccaggc	12540
taattttttg	tattttttagt	agagatgggg	tttcgccatg	ttggccaggc	tggtctcgaa	12600
ctcctgacct	caggtgatcc	gcccccttg	gcctcccaaa	gtgctaggat	tacagggtggg	12660
aaccacctcg	cccagcctgt	ggctatcggt	taaacactgg	gaaggcctgc	agcccccagg	12720
ccgacagtta	gctgcagctg	agcagttccc	agtgccagg	agacggatgc	tccaccacc	12780
tactcatggc	tgatctcttg	tcatagtgaa	gtgtctggac	agaccttcac	cgttatggga	12840
tctctggtcc	ccagagtggg	tggcaatgaa	tgggagtggg	caagctcacc	tgggtgtagg	12900
gggcagaggg	ccgaagtcca	gagtgtaccc	ccagagtggg	tgccagcagg	agcttgccga	12960

gggatctggg	atggagcagg	aggggtggagg	gaggagaccc	agaagagggg	gaactgtggg	13020
ccctgggtgg	gtctggagtg	cctggaggaa	gcccaggcgc	agagaggaga	agatgggatg	13080
ggtggcgagc	cccaggctgg	gccgacctca	cactgtgctc	tgtgcccctg	ccgtggacca	13140
ggtgagccat	acgtcgccat	caaggcctac	actgctgtgg	agggggacga	ggtgtccctg	13200
ctcgagggtg	aagctgttga	ggtcattcac	aagctcctgg	acggctggtg	ggtcatcagg	13260
taggagggcc	cctctccatc	cagagcaccc	atctgagtca	gccccagcca	ggacggcgtg	13320
tttagggatc	tgggggtgact	tgtccctggg	actctgggta	agccactgcc	cctctctggg	13380
cttagtttcc	atctcagtag	cagggaggaa	tgagcccacc	cttgccctgtc	ttgtggggat	13440
ccaaatgtct	tgtccaagtg	ggtgcatttc	tcctttgtga	tttaggggtc	cttcccaacc	13500
atctattatt	attccttctc	tggcaacatg	gtgaactggt	gtataaataa	ttacattcct	13560
agctaggcgc	aatggctcag	gcctgtaatc	ccagcacttt	gggagcccag	ggcaggacga	13620
tcacgtgagg	tcaggagttc	gagaccaccc	tggccaacat	ggcaaaaccc	tatctctact	13680
aaaaacacaa	acatgagccg	ggtgttgtgg	tgggagcctg	taatccccagc	tactcgggag	13740
tctcgagaca	agagaatcac	ttcaaccggg	gaggcggagg	ttgcagttag	ccaagatcgc	13800
gccattgcac	tccagcctgg	gcaacgagag	cgaactccg	tctcaaaaaa	aaaaaaaaaa	13860
aaaaatgatta	ctttcttttt	atcattcctt	tactttttaa	agctttcttg	cagtcagggtg	13920
cagtgtctca	tgcctgtaat	cccaacactt	tgggaagctg	aggtgggagg	atcactcaag	13980
gctacaagtt	caagaccaac	ctggccaatg	tagggagacc	tctgtctcta	caaaaaaaat	14040
taaaaaatag	ctggatgtgg	tagcacacac	ctgtagcccc	agctactcag	gaggctgagg	14100
tgaaaggatc	acttgacccc	aggagtggga	ggctgcagtg	agctatgact	gcaccactgc	14160
acccgagcct	gggtgatgga	gcaagaccct	gtctcaaaaa	aaaaaaaaaa	aaaaaagcct	14220
ccattgcaat	tcccatctgt	ttatcctcca	aatgaatgca	gaaataactaa	ttatcttttt	14280
tctggttctg	gggaacacag	aattctagcg	gcttggtggag	ccatttccct	ggagccatgg	14340
ggcctcccag	gtcctttcct	gtgtcttcac	tttttacgaa	ttttttcatt	ttttgagaca	14400
ggatcttget	ctgactccca	agctggagca	caatcatcgc	tcactcaagc	gatcctccca	14460
cctcaggctc	ccacgtagct	gggactacag	gtgagcacca	ccacatctgg	ctaagtgttt	14520
ttaatttttt	tgtagggatg	gggtctcact	atggtgccaa	gactagtctt	aaactcctgg	14580
cctcaagagt	tcctcctgcc	ttggcctccc	aaagcactgg	gattacagga	atgagcctcc	14640
atgctggggc	tttctggcg	tcttcagagc	cctaggtcac	agggccagcc	tggcgccctg	14700
ccgcaagctt	atcttaagc	tgggaccaca	acatgcatac	ctgcagccgg	gccccgggcc	14760
agagggtttt	gaggcagcat	ttctcagcct	tttagacaca	cactctgtta	acccccatcc	14820
tgtgtctctg	ataatcttct	tgtgatcctc	ccaccagcca	agaattgggt	tttatgtgaa	14880
ccttgtatta	tgcaaatgtt	tcttttgttt	tttttttcac	tcccaaatat	aatattgaga	14940
atagaaagaa	agtcttttca	acaaatgggtg	ctggaacaga	tggatttcca	tactggaaaa	15000
aaaaaaaaaa	gagcaaaaaa	caaacctaga	ccccttcctc	acactgtaca	catatgttta	15060
cttcagatgg	atcacagggt	tatccagag	taaaacttga	aactaaaaac	catttggggc	15120
tggacagggg	ctcacgcct	gtaatctcag	cactttggga	ggctgaggca	ggtggatcac	15180
ttgatgtcag	gagtttgaga	ccagccatga	ccaacatggt	gaaatcctgt	ctctactaaa	15240
aaaatacaaa	attaaccaag	tgtgggtggg	catgcctgta	atcccagcta	cttgggaagc	15300
tgagacagga	gaattgcttg	aacttgggaa	gcagagggtg	caatgagtcg	acatcatgcc	15360
attgcactcc	agcctaggca	acaagagcaa	aactctgtct	tgggggttggg	cgggggaaaa	15420
gcatttggaa	gaaagcatag	aatttgggtg	cttggaggta	ggcaaagggt	cgtaggagac	15480
agaaggcagt	taacataaaa	gaaaaattgg	caaatataat	cctgccagtg	tcttcttttt	15540
tctttaattt	tttcgggagg	tagagatagg	ggtcttgcta	tgtaaccag	gctgatctcc	15600
aactcctggc	ctcaagcgat	cctcccacct	agatccctca	aagtactggg	attacaggcg	15660
tgagcgaccg	tgccttgccc	attcttacca	atgtcatata	gctgataact	gtcccctgcg	15720
gtgacctgga	tctgctaacc	tccaccctt	ccttgactgt	ggaaggattg	ctggaagggt	15780
ctcagttgca	cagaccagga	aactgaggcc	cacagaggca	ggtgtccggg	tgtttgcaac	15840
ctctcagcct	gtgctaacc	caattgttca	gagagagccc	tgaaccctc	tcctctgggc	15900
gccccagggt	gactgcccc	gcctcaagg	ctgctctgt	tgcaggaaag	acgacgtcac	15960
aggctacttt	ccgtccatgt	acctgcaaaa	gtcaggggcaa	gacgtgtccc	aggcccaacg	16020
ccagatcaag	cggggggcgc	cgccccgcag	gtaagcgggg	gtccccgggg	ctgggcgggg	16080
tcgagcgggg	gcgcaccacg	ggttcgctct	gtctaggcca	tagcttggca	gtgccggggc	16140
gggggctctc	agcctggcag	gagaggcagg	acctcacagg	gggaaagggg	ctggacgcgc	16200
ctggccgcgg	tgtggggctg	gcacgggggc	ggaaggaaa	cggcgatgcc	cgggggcttt	16260
ggggatgggc	agtccagggg	ggctccccgg	agagggggac	gacagaccga	aggctggtga	16320

ggggcggtgga	aaaccgcccc	ggctctgctg	cagggaaggg	gtccttgctg	tgacggggggc	16380
agccgcctct	tgtcccgccg	gggtcgtgca	gactaccggc	cccctactgc	ccccacttc	16440
ctcggaccag	gggtgcccac	ctgagtcctt	gggggcaggg	gcgccctcgg	gctttgacga	16500
cgccccctcc	cgctggggcca	ggctgtccat	ccgcaacgtg	cacagcatcc	accagcggtc	16560
gcggaagcgc	ctcagccagg	acgcctatcg	ccgcaacagc	gtccgttttc	tgacgacgcg	16620
acgccgccag	gcgcggccgg	gaccgcagag	ccccgggagc	ccgctcggtg	agtgcagcgg	16680
agagggcagg	aagggaagc	cgtagaggcg	gagtcagcgg	gagaggcggg	gccagaggta	16740
gggccagagt	agcggggcgg	gaccagaggg	cggaatcaga	gggagaggcg	gggactggag	16800
gcggggtcag	aggaggagcc	agcgcttagg	gggcggagcg	atccctaaga	ggcggagtca	16860
gagggagagg	cacaagcggg	aggcgaggcc	agagcgcgga	gcaggagttg	gagaccgcgg	16920
cggggcgagg	ccagagagcg	ctgtggggcg	ggccagtgtg	cggggcgggg	cgtctgactc	16980
ggccccgctc	tctgcccgca	gaggaggagc	ggcagacgca	gcgctctaaa	ccgcagccgg	17040
cggtgcccc	gcggccgagc	gccgacctca	tcctgaaccg	ctgcagcgag	agcaccaagc	17100
ggaagctggc	gtctgccgtc	tgaggctgga	gcgcagtccc	cagctagcgt	ctcggccctt	17160
gccgcccttg	ccgccccgtg	cctgtacata	cgtgttctat	agagcctggc	gtctggacgc	17220
cgagggcagc	cccgaacctt	gtccagcgcg	gctcccgcca	ccctcaataa	atgttgcttg	17280
gagtggaaaa	aaaaaaaaaa	aa				17302